Published online 2024 March 10.

The Relationship Between Serum Folate and Homocysteine with Head and Neck Cancer: A Systematic Review and Meta-analysis

Mona Moghaddam Vahed 📴 1, Ayla Bahramian 🖻 2, Katayoun Katebi 🖻 2, * and Fatemeh Salehnia 🕮 3

¹Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran

²Department of Oral and Maxillofacial Medicine, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran

³Research Center for Evidence Based Medicine (RCEBM), Tabriz University of Medical Sciences, Tabriz, Iran

*Corresponding author: Department of Oral and Maxillofacial Medicine, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran. Email: k.katebi@yahoo.co.uk

Received 2023 September 13; Revised 2023 November 25; Accepted 2024 February 21.

Abstract

Context: Early diagnosis of head and neck squamous cell carcinomas (HNSCC) is critical for preventing further disease progression. This study aimed to compare the serum folate and homocysteine levels in patients with HNSCC and healthy controls through a systematic review and subsequent meta-analyses.

Evidence Acquisition: The research question was: Is there a difference between serum folate and homocysteine levels (O) of patients with HNSCC (E) compared to healthy controls (C)? To conduct a systematic review, keywords were first identified and then searched in Medline/PubMed, Web of Science, ProQuest, EMBASE, Scopus, and Google Scholar databases within the period from January 2000 to November 2023. The searched studies were screened based on inclusion and exclusion criteria, and after assessing the quality of the selected articles using the Joanna Briggs Institute assessment checklist, 10 articles were finally included in the meta-analysis (nine articles for serum folate and eight for homocysteine). Due to the heterogeneity of studies, meta-analyses were conducted according to the random-effects model. Several meta-analyses were carried out because the selected articles were not uniform regarding smoking habits.

Results: Regardless of smoking conditions, the serum folate levels of the HNSCC patients were significantly lower than those of the control groups. Similarly, the serum homocysteine levels were significantly higher in the patient groups compared to the control groups.

Conclusions: The meta-analyses in this study showed an association between serum folate and homocysteine levels with HNSCC, indicating their possible use as biomarkers for the early detection of HNSCC.

Keywords: Folate, Head and Neck Squamous Cell Carcinoma, Homocysteine, Meta-analysis

1. Context

Head and neck squamous cell carcinomas (HNSCCs) are the most common malignancies affecting the oral cavity, pharynx, and larynx (1, 2). Despite advancements in HNSCC treatment, it still exhibits a low 5-year survival rate of approximately 40 percent (3). Many potential biochemical markers associated with head and neck malignancies originate from the methionine cycle. Methionine, a crucial amino acid, is essential for normal human growth and participates in numerous metabolic pathways (4, 5). Homocysteine (Hcy), an intermediate metabolite in the methionine cycle, influences all methyl and sulfur groups involved in bodily metabolism. DNA methylation plays a crucial role in gene expression, thereby affecting phenotype changes (6). Folate is

responsible for remethylating Hcy back to methionine (7). Elevated serum Hcy levels are often linked to folate deficiency (8).

Several studies have documented a significant correlation between the occurrence of HNSCC and decreased serum folate (9-16), as well as increased serum Hcy levels (9, 10, 12, 13, 15, 17, 18). In a systematic review encompassing four studies, HNSCC patients exhibited significantly lower serum folate levels compared to controls (19).

Early detection of HNSCC through biomarkers holds promise in preventing disease progression. Hence, this study aimed to explore the association between serum folate and Hcy levels and HNSCC. To the best of our knowledge, no meta-analysis has yet been conducted on

Copyright © 2024, Moghaddam Vahed et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

these associations.

2. Evidence Acquisition

The research question addressed whether there is a difference in serum folate and Hcy levels between patients with HNSCC and healthy controls.

2.1. Literature Search and Study Selection

To conduct a systematic review, literature searches were performed using MeSH and free terms based on the PECO (Population, Exposure, Comparator, and Outcomes) strategy across multiple databases, including Medline/PubMed, Web of Science, Google Scholar, ProQuest, EMBASE, and Scopus. Additionally, reference lists and citations of included articles were reviewed for further relevant studies. A comprehensive search was carried out, including ProQuest for dissertations, Google Scholar for conference papers, and https://greymatters.cadth.ca/ for gray literature. The search strategy involved various combinations of terms such as folic acid, folate, pteroylglutamic acid, folvite, folacin, vitamin B9, vitamin M, homocysteine, Hcy, 2-amino-4-mercaptobutyric acid, squamous cell carcinoma, head and neck, oral, HNSCC, OSCC, oral tongue, oral cavity, laryngeal, larynx, nasal cavity, nasopharyngeal, hypopharyngeal, mouth, oropharyngeal, salivary gland, lip, cervical tracheal, tracheal, neoplasm, cancer, biomarker.

The inclusion criteria for selecting studies were articles published in English until November 20, 2023, case-control or cohort studies involving newly diagnosed, untreated HNSCC patients with histopathologically confirmed diagnosis and measurement of serum levels of Hcy and folate, and no restriction on age. Exclusion criteria comprised letters to the editors, meta-analyses, or systematic reviews.

2.2. Data Extraction

Following the extraction of articles from the selected databases, two authors (MMV and KK) independently assessed them. Any discrepancies were resolved by a third author (AB). Articles were screened based on title, abstract, and full text, with those meeting the inclusion criteria selected for further analysis. Extracted data included primary author name, location, publication year, study design, sample size of cases and controls, type of sample specimens, serum folate and Hcy levels with standard deviation in HNSCC patients and control groups, and any subgroup data (e.g., smokers or non-smokers), along with confounding factors in each study.

2.3. Assessment of the Risk of Bias

The retrieved articles underwent evaluation by two independent authors (K.K and M.M.V) utilizing the Joanna Briggs Institute (JBI) assessment checklist comprising 10 items. This checklist aimed to assess the methodological quality of the selected articles and identify potential biases in design, conduct, and analysis, such as appropriate case-control matching, measurement reliability, identification of confounding factors, and utilization of suitable statistical analysis (20). Articles with a JBI checklist score of \geq 7 were deemed high-quality. In instances of disagreement between the two evaluators, a third evaluator (A.B.) was consulted.

2.4. Statistical Analysis

Meta-analysis was conducted based on sample size, mean, and standard deviation. The heterogeneity among studies was evaluated using the I2 index and the chi-square test. Given the significant heterogeneity observed between studies and I2 values exceeding 50%, the random-effects model was employed for the meta-analyses (21). Publication bias was assessed using the Egger linear regression model (22) and the Begg and Mazumdar rank correlation test (23). The pooled mean difference between case and control groups for serum folate and Hcy levels, along with its 95% confidence interval, was utilized to identify associations between serum folate/Hcy and HNSCC occurrence. Statistical analyses were performed using STATA (version 12).

While most studies included in the meta-analysis assessed both smoking and non-smoking patients, the majority did not report serum folate and Hcy levels separately for these subgroups (9, 14, 17). However, most of these studies separated serum folate and Hcy levels between smoker and non-smoker controls (9, 10, 12-16). To approximate the confounding effect of smoking on serum folate and Hcy levels in relation to HNSCC, five meta-analyses were conducted for smoking and/or non-smoking conditions, along with a meta-analysis comparing smoker controls with non-smoker controls.

3. Results

3.1. Summary of Study Search and Characteristics

The literature search yielded 1 425 articles after removing duplicate papers within EndNote. Out of the 21 articles that underwent full review, 12 were included in the systematic review. However, only 10 studies were eligible for the meta-analysis, as two studies (18, 24) did not report means and standard deviations. Figure 1 illustrates the search results and screening process.



Figure 1. PRISMA flow diagram of the search results and selection process for inclusion in the systematic review

Of the selected articles, eleven were case-control studies, and one was a cohort study. These articles originated from European (n = 5), Asian (n = 6), and African (n = 1) countries. The types of squamous cell carcinoma cancers studied included comprehensive HNSCC (n = 6), laryngeal (n = 3), and oral cavity (n = 3). The sample sizes varied across the included studies in the meta-analysis, ranging as follows: For the relationship between serum folate levels and HNSCC (493 - 1240 cancer patients; 355 - 1342 controls) and for the relationship between serum Hcy levels and HNSCC (428 - 987 cancer patients; 327 - 1277 controls). A summary of the main characteristics of the included studies in the systematic review and meta-analyses is provided in Tables 1 and 2 for the folate

and Hcy studies, respectively. In the majority of studies utilized for the meta-analysis, important confounding factors were either matched between patients and controls or adjusted for.

3.2. Assessment of the Risk of Bias

According to the JBI tool, out of the 12 included studies, 11 had a low risk of bias, while one study was identified with a moderate risk of bias (Table 3).

3.3. Meta-analysis for Folate

The results of various meta-analyses are presented in Table 4 and Figure 2. The number of studies included ranged from 6 to 9. In all meta-analyses concerning

Articles	Country	Study Design	Cancer Type	Sample Size (Patients)	Sample Size (Controls)	Folate Level in Patients, ng/mL	Folate Level in Controls, ng/mL	Matched Factors Between Patients and Controls and/or Adjustments
Akinmoladun and Arinola (18), 2019 ^a	Nigeria	Case-control	HNSCC	Total: 30; smoker: 19; nonsmokers: 11	Total: 30; smoker: 2; nonsmokers: 28	26.05 (Median)	30.82 (Median)	Not included in the meta-analysis
Chang et al. (11), 2016	China	Case-control	LSCC	Total: 60; nonsmokers: 60	Total: 30; nonsmokers: 30	3.35	4.40	Matched: No diseases affecting the outcome, no vitamin B intake
Erugula et al. (13), 2016	India	Case-control	OSCC	Total: 30; smokers: 30	Total: 30; smokers: 15; nonsmokers: 15	5.34	Smokers: 7.68; nonsmokers: 10.99	Matched: No diseases affecting the outcome, not receiving affecting drugs
Fanidi et al. (17), 2015	10 European countries	Cohort	HNSCC	Total: 516; smokers: 256; ex-smokers ^b : 145; nonsmokers: 105; unknown: 10	516 (matched control); smokers: 104; ex-smokers: 184; nonsmokers: 214; unknown: 14	12.5	12.9 (matched control)	Matched: Country, age, gender, not other cancer, date of blood collection
Gorgulu et al. (14), 2010	Turkey	Case-control	ISCC	Total: 60; smokers: 56; nonsmokers: 4	Total: 60; smokers: 30; nonsmokers: 30	5.8	Smokers: 7; nonsmokers: 7,1	Matched: Geographic area, age, low to moderate alcohol intake, normal renal function, no hepatic failure, no receiving affecting drugs, no folic acid and vitamin B12 intake, no nutritional deficiency
Nacci et al. (15), 2008	Italy	Case-control	LSCC	Total: 25; smoker: 13; ex-smoker: 12	Total: 80; smoker: 25; ex-smoker: 30; nonsmokers: 25	4.3; smoker: 4.6; ex-smoker: 3.8	7.9; smoker: 7.5; ex-smoker: 8; nonsmokers: 8.1	Adjustment: Age, gender, alcohol intake, cardiovascular disease
Eleftheriadou et al. (12), 2006	Greece	Case-control	HNSCC	Total: 149; smoker: 131 nonsmokers: 18	Total: 150; smoker: 77; nonsmokers: 73	5.32	Smoker: 5.95; nonsmokers: 8.75	Matched: Geographic area, age, gender, no systematic alcohol intake, normal renal function, no folate intake
Almadori et al. (10), 2005	Italy	Case-control	HNSCC	Total: 144; smoker: 129; nonsmokers: 15	Total: 210; smoker: 90; nonsmokers: 120	4.87	Smokers: 9.1; nonsmokers: 9.7	Matched: Geographic area, age, gender, no habitual alcohol intake, normal renal function, no folate intake, no nutritional deficiency
Almadori et al. (9), 2002	Italy	Case-control	HNSCC	Total: 42; smoker: 39; nonsmokers: 3	Total: 210; smoker: 90; nonsmokers: 120	5.8	Smoker: 9.1; nonsmokers: 9.7	Matched: Geographic area, age, gender, low to moderate alcohol intake
Raval et al. (16), 2002	India	Case-control	HNSCC	Total: 214; smoker: 188; nonsmokers: 26	Total: 56; smoker: 28; nonsmokers: 28	11.083; smoker: 10.83; nonsmokers: 12.89	11.14; smoker: 11.45; nonsmokers: 10.83	Adjustment: Age, area, education, income

Abbreviations: HNSCC, head and neck squamous cell carcinoma; LSCC, laryngeal squamous cell carcinoma; OSCC, oral squamous cell carcinoma. ^a This article was not included in the meta-analysis due to the lack of data for means and standard deviations.

^b Ex-smokers were regarded as non-smokers.

serum folate, the heterogeneity test yielded significant results (Q = 30.0 - 208.0, df = 5 - 8, P-value < 0.001, $I^2 = 83.3 - 96.8$). Consequently, the outcomes were reported using the random effects model. The pooled mean differences between patients and controls across the studies ranged from -2.24 to -2.71 ng/ml of folate, all of which were statistically significant (P-value 0.003 - < 0.001). The negative signs in all analyses indicate that the serum folate level in the HNSCC patient group was lower than that in the control group. Meta-analysis No. 6 (as depicted in Table 4 and Figure 2) compared smoking controls with non-smoking healthy individuals, revealing significantly lower serum folate levels in the smoking controls compared to the non-smoking controls (mean difference = -1.15 ng/mL, P-value = 0.05). All meta-analyses suggested no indication of publication bias, as the Egger test and Begg and Mazumdar test results were not significant (Table 4). The forest plots regarding folate from the meta-analyses are illustrated in Figure 2.

3.4. Meta-analysis for Homocysteine

The types of meta-analyses for serum Hcy were similar to those for serum folate (Table 5 and Figure 3). The number of studies included in different meta-analyses for Hcy ranged from 6 to 8. All meta-analyses for serum Hcy levels were conducted using the random effects model because all heterogeneity tests were significant (Q=19.7-145.7, df = 5 - 7, P-value < 0.001, $I^2 = 74.7 - 96.2$). The differences between the means of HNSCC and control groups for serum Hcy, pooled over studies, were significant in the meta-analyses (P-value < 0.001) and ranged from 3.56 to 5.60 μ M/L. This indicates that the serum Hcy level in the cancer group was higher than in the control group. Although the highest mean difference belonged to the meta-analysis in which

	No.	Ecrest plot	
N Normal probability	110.	Forest plot	
Image: properties of the properties	1		
		Model Study name Statistics for each study Difference in means and 95% C	
		Difference Standard Lower Upper in means error Variance limit limit Z-Value p-Value	
		Chang et al., 2016 -1.050 0.335 0.112 -1.706 -0.394 -3.137 0.002	
		Erugua et al., 2016 -4.000 0.654 0.428 -5.282 -2.718 -6.117 0.000 -	
		Gorgulu et al., 2010 -1.250 0.484 0.234 -2.199 -0.301 -2.682 0.010	
1 1		Nacci et al., 2008 -3.660 0.543 0.295 -4.725 -2.595 -6.738 0.000	
2 2 100 </th <th></th> <th>Almadori et al., 2005 -4.570 0.254 0.065 -5.068 -4.072 -17.972 0.000</th> <th></th>		Almadori et al., 2005 -4.570 0.254 0.065 -5.068 -4.072 -17.972 0.000	
Name Description <		Almadori et al. 2002 -3.640 0.399 0.159 -4.423 -2.857 -9.117 0.000	
2 10 10 10 10 10 2 10		Random -2.289 0.017 0.381 -3.498 -1.079 -3.709 0.000	
2 1 <th></th> <th>-10.00 -5.00 0.00 5.00</th> <th>10.00</th>		-10.00 -5.00 0.00 5.00	10.00
- Image: signam <	2		
Network	2		
Image:		Model Study name Statistics for each study Difference in means and 95% C	21
3 Image: mining intermediate intermed		Difference Standard Lower Upper in means error Variance limit limit Z-Value p-Value	
3 Market al., 2019 0.00 </th <th></th> <th>Erugula et al., 2016 -4.000 0.654 0.428 -5.282 -2.718 -6.117 0.000</th> <th></th>		Erugula et al., 2016 -4.000 0.654 0.428 -5.282 -2.718 -6.117 0.000	
3 Market al. 2001 1.00 0.00 <th></th> <th>Fanidi et al., 2015 -0.170 0.240 0.057 -0.640 0.300 -0.709 0.478</th> <th></th>		Fanidi et al., 2015 -0.170 0.240 0.057 -0.640 0.300 -0.709 0.478	
1 Interce of all 2000 1.000 0.		Gorgulu et al., 2010 -1.250 0.484 0.234 -2.199 -0.301 -2.582 0.010	
$\frac{1}{9}$		Nacci et al., 2008 -3.660 0.543 0.295 -4.725 -2.595 -6.738 0.000	
A mandari di 2,002 1 000 0000 000 000 000 000 000 000 0		Eleftheriadou et al., 2006 -1.990 0.248 0.062 -2.476 -1.504 -8.019 0.000	
1 100		Almadori et al. 2005 -4.570 0.254 0.065 -5.068 -4.072 -17.972 0.000	
Runce 2.48 0.68 0.473 - 379 - 1100 - 330 - 000 Image: distance of the stand of the		Raval et al. 2002 -0.060 0.935 0.874 -1.893 1.773 -0.064 0.949	
3 Image: set of the		Random -2.448 0.688 0.473 -3.795 -1.100 -3.560 0.000	
3 100 100 100 100 100 100 3 1000000000000000000000000000000000000			'
3 Model Hudge name Interacts of section Lower Upper Environment Difference in means and BY-C Fainds et al., 2015 0.170 0.240 0.057 0.240 0.302 0.259 0.470 Nodel Hudge name 0.200 0.440 0.224 0.400 0.302 0.470 0.240 0.007 0.400		-10.00 -5.00 0.00 5.00	10.00
Media National procession Difference in means and BP.CI Immedia <	3		
Image:		Model Study name Statistics for each study Difference in means and	95% CI
Image: 1, 2015 1, 120 0, 007 0, 00		Difference Standard Lower Upper	
A A		Fanidi et al., 2015 -0.170 0.240 0.057 -0.640 0.300 -0.709 0.478	1 1
A A		Gorgulu et al. 2010 -1.250 0.484 0.234 -2.199 -0.301 -2.582 0.010	
Image: state stat		Nacci et al. 2008 -3.660 0.543 0.295 -4.725 -2.595 -6.738 0.000	
Amadori et al. 2000 1.570 0.55 0.065 0.00 <t< th=""><th></th><th>Eleftheriadou et al., 2006 -1.990 0.248 0.062 -2.476 -1.504 -8.019 0.000</th><th></th></t<>		Eleftheriadou et al., 2006 -1.990 0.248 0.062 -2.476 -1.504 -8.019 0.000	
Amadori et al. 2002 3.84 0.99 0.194 4.82 2.87 0.117 0.00 <t< th=""><th></th><th>Almadori et al. 2005 -4.570 0.254 0.065 -5.068 -4.072 -17.972 0.000</th><th></th></t<>		Almadori et al. 2005 -4.570 0.254 0.065 -5.068 -4.072 -17.972 0.000	
Award et al. 2002 0.000 0.035 0.044 - 1.040 1.773 0.044 0.00		Almadori et al. 2002 -3 640 0.399 0.159 -4 423 -2.857 -9.117 0.000	
Andorn 223 0.70 0.94 3-367 - 076 3-020 0.01		Raval et al. 2002 -0.060 0.935 0.974 -1.893 1.773 -0.064 0.949	
Image: 100 model with the first of each study Interact of means and 95% of 100 model with the first of each study Interact of means and 95% of 100 model with the first of each study Interact of means and 95% of 100 model with the first of each study Interact of means and 95% of 100 model with the first of each study 3 Model Study name Study of 200 model with the first of each study Interact of means and 95% of 100 model with the first of each study Interact of all with the first of each study Interact of all with the first of each study Interact of all with the first of each study 3 Model Study name Study of 200 model with the first of each study Interact of all with the first of each study Interact of all with the first of each study Interact of all with the first of each study 3 Model Study name Study of all with the first of each study Interact of all with the first of each study Interact of all with the first of each study 3 Model Study name Study of all with the first of each study Interact of all with the first of each study Interact of all with the first of each study 4 Model Study name Study of all with the first of each study Interact of all with the first of each study Interact of all with the first of each study 5 Model Study name Study of all with the first of each study		Random -2.236 0.740 0.548 -3.687 -0.785 -3.020 0.003	
Image: statistic statisti			' '
4 Image: Study name Substrict for each study Difference in means and 95% CI Engula et al., 2019 1.200 0.600 0.900 0.000 1.000 Amadori et al., 2008 2.900 0.600 0.900 1.000 0.000 1.000 Amadori et al., 2008 2.900 0.600 0.1002 1.227 0.600 1.000 0.000<		-10.00 -5.00 0.00 f	5.00 10.00
Morie Turpume et al, 2000 1000 Difference Turpume et al, 2000 1000 </th <th>4</th> <th></th> <th></th>	4		
Image: root number of the sector of		Model Study name Statistics for each study Difference in means and 955	
S Immension Terrer Name Nam		Difference Standard Lower Upper	
S Model Study name Extistics for each study Difference in means and 95% CI Changed et al. 2006 -3.49 0.07 0.024 -3.88 -0.09 0.007 Aimsdori et al. 2000 -1200 0.069 0.484 -0.29 0.069 0.007 0.007 Aimsdori et al. 2002 -0.200 0.069 0.489 -1207 0.003 1.007 0.000 Aimsdori et al. 2002 -0.200 0.220 1.007 1.091 1.089 0.480 0.220 0.001 1.007 0.000 0.001 0.00		in means error Variance limit limit Z-Value p-Value	
Sorgalize et al., 2000 -1.200 0.630 0.307 -2.440 0.054 0.007 0.007 Histhersdou et al., 2000 -0.630 0.300 0.107 1.877 -0.000 0.000 0.007 0.000 <th> </th> <th></th> <th></th>			
S Image of et al., 2000 0.000 <th></th> <th>Erugula et al., 2016 -2.340 0.790 0.624 -3.888 -0.792 -2.963 0.003</th> <th></th>		Erugula et al., 2016 -2.340 0.790 0.624 -3.888 -0.792 -2.963 0.003	
S Model Study name Statistics for each study Difference in means and 95% CI 6 Model Study name Statistics for each study Difference in means and 95% CI 6 Model Study name Statistics for each study Difference in means and 95% CI 6 Model Study name Statistics for each study Difference in means and 95% CI 6 Model Study name Statistics for each study Difference in means and 95% CI 7 Model Study name Statistics for each study Difference in means and 95% CI 7 Model Study name Statistics for each study Difference in means and 95% CI 7 Model Study name Statistics for each study Difference in means and 95% CI 7 Model Study name Statistics for each study Difference in means and 95% CI 7 Model Study name Statistics for each study Difference in means and 95% CI 7 Model Study name Statistics for each study Difference in means and 95% CI 7 Model Study name Statistics for each study Difference in means and 95% CI 7 Model Study name Statistics for		Erugula et al. 2016 -2.340 0.790 0.624 -3.888 -0.792 -2.963 0.003	
Ammaderie et al. 2000 3.00 0.00 1.00 <t< th=""><th></th><th>Eruguda et al., 2016 -2.340 0.790 0.624 -3.889 -0.792 -2.963 0.003 Gorgulu et al., 2010 -1.200 0.630 0.397 -2.434 0.034 -1.905 0.057 Nacci et al., 2008 -2.900 0.989 0.488 -4.289 -1.531 -4.153 0.000</th><th></th></t<>		Eruguda et al., 2016 -2.340 0.790 0.624 -3.889 -0.792 -2.963 0.003 Gorgulu et al., 2010 -1.200 0.630 0.397 -2.434 0.034 -1.905 0.057 Nacci et al., 2008 -2.900 0.989 0.488 -4.289 -1.531 -4.153 0.000	
Model Study et al. 2002 0.020 0.120 1.012 0.100 0.000		Enguda et al., 2016 - 2-340 0.700 0.424 - 3.680 0.702 - 2.403 0.003 Gorgula et al., 2016 - 1.200 0.830 0.397 - 2.434 0.034 - 1.505 0.057 Nacci et al., 2008 - 2.600 0.490 0.496 - 1.420 0.034 - 1.505 0.057 Eterthremisduo et al., 2008 - 0.630 0.320 0.102 - 1.227 - 0.003 - 1.977 0.049 Minimum et al. 0.000 - 0.630 0.320 0.102 - 1.227 - 0.003 - 1.977 0.049	
Random 2,248 0.683 0.407 3,587 0.909 0.201 0.00 4.00 0.00		Enguda et al., 2016 -2.40 0.700 0.624 -3.680 0.792 -2.495 0.003 Gorguta et al., 2010 -1.200 0.630 0.307 -2.434 0.034 -1.906 0.657 Nacci et al., 2008 -2.600 0.669 0.448 -4.206 -1.551 -4.150 0.000 Eleftheriadou et al., 2006 -0.630 0.320 0.102 -1.257 -0.003 -1.971 0.049 Annadori et al., 2006 -4.230 0.322 0.107 -4.672 -3.568 -1.2911 0.000	
5 Model Study name Character et al., 2006 Autor et al., 2007 Control et al., 20		Enguda et al., 2016 -2.340 0.790 0.624 -3.888 -0.792 -2.963 0.003 Gorgula et al., 2010 -1.200 0.530 0.97 -2.434 0.034 -1.056 0.657 Nacci et al., 2008 -2.900 0.690 0.488 -4.269 -1.531 -4.153 0.000 Eletherisadou et al., 2005 -0.630 0.320 0.102 -1.257 -0.003 -1.971 0.049 Almadori et al., 2002 -3.300 0.472 0.223 -4.225 -2.375 -0.499 0.000 Bavade et al., 2002 -0.102 -1.202 -1.202 -0.203 -0.591 0.000	
S Indel Study name Statistics for each study Difference in means and 95% CI Chang et al., 2010 -1.30 0.07 1.00 1.00 0.00 <		Enguda et al. 2016 - 2-340 0.700 0.424 - 3.880 0.702 - 2.803 0.003 Gorgulu et al. 2016 - 1200 0.530 0.397 - 2.434 0.034 - 1305 0.057 Nacci et al. 2009 - 2.800 0.480 - 4.269 1.531 - 4.153 0.000 Elethremisdue et al. 2005 - 0.630 0.320 0.102 - 1.257 - 0.003 - 1.971 0.499 Almadori et al. 2005 - 0.420 0.320 0.102 - 1.257 - 0.003 - 1.971 0.499 Almadori et al. 2002 - 0.820 0.320 0.102 - 1.257 - 0.003 - 1.971 0.499 Rawate et al. 2002 - 0.620 1.272 1.127 - 1.012 - 3.109 1.209 0.000 Rawate et al. 2002 - 0.620 1.270 1.127 0.19 1.890 - 0.480 0.625 Rawate et al. 2002 - 0.620 0.472 0.23 - 4.272 - 0.990 - 3.200 0.01	
S Difference in means and 95%.C ¹ 6 Model Study name Statistics for each study Difference in means and 95%.C ¹ 0 Model Study name Statistics for each study Difference in means and 95%.C ¹ 0 Model Study name Statistics for each study Difference in means and 95%.C ¹ 0 Model Study name Statistics for each study Difference in means and 95%.C ¹ 0 Model Study name Statistics for each study Difference in means and 95%.C ¹ 0 Model Study name Statistics for each study Difference in means and 95%.C ¹ 0 Model Study name Statistics for each study Difference in means and 95%.C ¹ 0 Model Study name Statistics for each study Difference in means and 95%.C ¹ 0 Model Study name Statistics for each study Difference in means and 95%.C ¹ 0 Model Study name Statistics for each study Difference in means and 95%.C ¹ 1 Model Study name Statistics for each study Difference in means and 95%.C ¹ 1 Model Study name Statistics for each study Difference in means and 95%.C ¹ 1 Model Study name Statistics for each study Difference in means and 95%.C ¹ 1 Model Study name Statistics for each st		Enguda et al. 2016 - 2-340 0.700 0.424 - 3.880 0.702 - 2.403 0.003 Gorgula et al. 2016 - 1200 0.630 0.397 - 2.434 0.034 - 1.505 0.567 Nacci et al. 2008 - 2.600 0.484 - 4.206 0.648 - 4.206 0.004 Eleftmerisadou et al. 2006 - 4.330 0.320 0.102 - 1.257 - 0.003 - 1.571 0.415 0.000 Almadori et al. 2006 - 4.330 0.320 0.102 - 1.257 - 0.003 - 1.571 0.415 0.000 Almadori et al. 2002 - 0.200 1.270 1.272 - 2.358 - 1.2911 0.000 Rawal et al. 2002 - 0.620 1.270 1.612 - 3.109 1.809 - 0.448 0.625 Random 2.248 0.803 0.467 - 3.587 - 0.590 - 3.250 0.001	
Model Study name Extistics for each study Difference in means and 95% CI Chang et al., 2016 1.05 0.11 1.01 0.00 1.01 Gorgulu et al., 2008 0.07 5.80 2.24 1.01 0.00 0.00 Amadori et al., 2002 0.80 0.57 4.80 0.00 0.01 0.00		Enguda et al., 2016 - 2.340 0.700 0.624 - 3.889 0.792 - 2.893 0.003 Gorgula et al., 2010 - 1.200 0.630 0.397 - 2.434 0.034 - 1.906 0.697 Nacci et al., 2008 - 2.400 0.030 - 1.531 - 4.150 0.000 Eleftheriadou et al., 2006 - 0.630 0.320 0.102 - 1.557 - 0.003 - 1.571 0.049 Almadori et al., 2002 - 3.300 0.472 0.223 - 4.226 - 2.375 - 4.990 0.000 Revale et al. 2002 - 0.620 0.77 1.612 - 3.169 0.480 0.625 Random - 2.248 0.683 0.467 - 3.587 0.909 - 3.260 0.001	8.00
Model study many Statistics for each study Difference in means variance interim limit 200 del 100 Difference interesting and the statistics for each study Difference in means and 95% CI Chang et al. 2001 -1.30 0.37 -2.00 -0.00 -0.00 0.00	5	Enguda et al., 2016 -2.340 0.790 0.624 -3.888 0.772 -2.663 0.003 Gorgua et al., 2010 -1.200 0.630 0.397 -2.434 0.034 1.906 0.057 Nacci et al., 2020 -2.630 0.690 0.488 -4.290 1.531 -4.153 0.000 Elettheriadou et al., 2006 -0.630 0.320 0.102 -1.257 -0.003 -1.971 0.049 Almadori et al., 2002 -0.630 0.320 0.107 -4.872 -3.588 -1.2911 0.000 Almadori et al., 2002 -0.620 0.027 1.127 0.149 0.040 Raval et al. 2002 -0.228 0.027 1.127 0.198 0.488 0.855 Random -2.248 0.683 0.467 -3.587 -0.909 -3.290 0.001	8.00
Immerants Variance Immi finit Zvaluep-Value Chang et al. 2016 -1.03 0.37 -2.50 -0.11 -1.71 -0.39 -3.41 0.00 Biotheristo et al. 2008 -4.25 0.07 -5.86 -2.24 0.00 -0.00	5	Enguda et al. 2016 - 2-340 0.700 0.624 -3.680 0.702 - 2.603 0.003 Gorgula et al. 2016 - 1200 0.630 0.397 - 2.434 0.034 - 1365 0.057 Nacci et al. 2008 - 2.600 0.488 - 4.269 1.531 - 4.153 0.000 Elethremisduoi et al. 2006 - 0.630 0.320 0.102 - 1.257 - 0.003 - 1.571 0.049 Almadori et al. 2002 - 3.200 0.472 0.223 - 4.256 - 3.756 - 9.690 0.000 Rewat et al. 2002 - 0.620 1.270 1.012 - 3.109 1.089 - 0.488 0.625 Random - 2.248 0.683 0.467 - 3.587 - 0.909 - 3.250 0.001	8.00
Change et al., 2016 -1.05 0.11 -1.71 -0.39 -3.14 0.00 Gorgulut et al., 2016 -3.010 -1.30 0.37 -2.60 -0.10 -2.12 0.00 Nacci et al., 2003 -4.25 0.67 -5.86 -2.64 -5.18 0.00 Amadori et al., 2002 -4.33 0.06 -5.37 -2.91 -1.28 0.00 Amadori et al., 2002 -4.33 0.06 -5.37 -2.91 -1.28 0.00 Rawaf et al., 2002 -2.06 2.77 -1.20 5.32 1.24 0.00 Rawaf et al., 2002 2.06 2.77 -1.20 5.32 1.24 0.20 Rawaf et al., 2002 2.06 2.77 -1.20 5.32 1.24 0.20 Rawaf et al., 2004 -0.07 0.40 0.00 4.00 0.00 4.00 8.00 Correct et al., 2004 -0.51 0.35 -1.12 2.02 0.00 4.00 8.00	5	Enguda et al., 2016 - 2-340 0.790 0.624 - 3.889 0.792 - 2.893 0.003 Gorgula et al., 2016 - 1.200 0.630 0.397 - 2.434 0.034 - 1.306 0.057 Nacci et al., 2020 - 2.430 0.320 0.102 - 1.257 - 0.03 - 1.571 0.610 Eletherisadou et al., 2006 - 0.630 0.320 0.102 - 1.257 - 0.03 - 1.571 0.049 Annadori et al., 2002 - 3.200 0.74 0.72 - 2.354 - 2.375 0.490 0.000 Raval et al. 2002 - 0.620 1.270 1.812 - 3.109 1.809 - 0.488 0.625 Random - 2.248 0.683 0.467 - 3.587 - 0.909 - 3.290 0.001 -0.00 0.00 4.00 Model Study.name Model Study.name Model Study.name Difference Lower Upper	8.00
Model 8 Judy name Statistics for each study Difference in means and 95%CI 6 Model 8 Judy name Statistics for each study Difference in means and 95%CI 6 Model 8 Judy name Statistics for each study Difference in means and 95%CI 6 Model 8 Judy name Statistics for each study Difference in means and 95%CI 6 Model 8 Judy name Statistics for each study Difference in means and 95%CI 6 Model 3 Judy name Statistics for each study Difference in means and 95%CI 6 Model 3 Judy name Statistics for each study Difference in means and 95%CI 7 0.30 0.31 1.16 0.52 0.20 0.80 6 Model 3 Judy name Statistics for each study Difference in means and 95%CI Statistics for each study Statistics for each study	5	Enguda et al., 2016 - 2.340 0.790 0.624 - 3.889 0.792 - 2.843 0.003 Gorgula et al., 2010 - 1.200 0.630 0.397 - 2.434 0.004 - 1.906 0.057 Nacci et al., 2008 - 2.400 0.630 0.320 0.102 - 1.257 - 0.003 - 1.571 0.049 Almadori et al., 2000 - 0.630 0.320 0.102 - 1.257 - 0.003 - 1.571 0.049 Almadori et al., 2002 - 3.300 0.472 0.223 - 4.226 - 2.375 - 4.990 0.000 Reval et al. 2002 - 0.620 1.27 1.612 - 3.109 0.800 0.625 Random - 2.248 0.683 0.467 - 3.587 0.909 - 3.280 0.011 Model Studyname Etatistics for each study Difference in means and 95% CC Difference in means Variance limit Zyahupey-Value	8.00
Elemenadou et al., 2006 -3.43 0.07 -3.95 -2.91 1.28 0.00 Amadori et al., 2005 -3.80 0.06 -5.37 -1.20 1.20 1.20 Amadori et al., 2002 2.66 2.77 -1.20 5.32 1.24 0.22 Randori et al., 2002 2.66 2.77 -1.20 5.32 1.24 0.22 Randori et al., 2002 2.66 2.77 -1.20 5.32 1.24 0.22 Randori et al., 2002 2.66 2.77 -1.20 5.32 1.24 0.20 6 Imagori et al., 2016 -3.31 1.00 -1.42 -1.20 0.00 4.00 6.00 10 Freeroe Immes Variance Imit Itimit Zvalues-Value Immes Values-Value Immes Values-Values-Value Immes Values-Value	5	Enguda et al., 2016 - 2-340 0.700 0.424 - 3.880 -0.702 - 2.803 0.003 Gorgula et al., 2016 - 1200 0.830 0.397 - 2.434 0.034 - 1305 0.057 Nacci et al., 2009 - 2.800 0.488 - 4.269 1.531 - 4.153 0.000 Elethremadou et al., 2005 - 4.230 0.320 0.102 - 1.257 - 0.003 - 1.971 0.469 Almadori et al., 2005 - 4.230 0.328 0.107 - 4.672 - 3.589 - 1.2911 0.000 Almadori et al., 2002 - 0.620 1.270 1.912 - 3.109 1.809 - 0.488 0.625 Random - 2.248 0.683 0.467 - 3.587 - 0.909 - 3.250 0.001 Model Studyname Statistics for each study Difference Innews and 95% C Denog et al., 2016 - 1.05 0.11 - 1.71 - 0.39 - 3.14 0.00 Chang et al., 2016 - 1.05 0.11 - 1.71 - 0.39 - 3.14 0.00 Chang et al., 2016 - 1.05 0.11 - 1.71 - 0.39 - 0.00	800 800
Aimadori et al., 2005 -4.83 0.06 -5.37 -1.20 -1.20 0.00 Ravadori et al., 2002 2.06 2.77 -1.20 5.32 1.24 0.02 Ravad et al. 2002 2.06 2.77 -1.20 5.32 1.24 0.02 Random -2.71 0.43 -4.00 1.20 -8.00 -4.00 0.00 4.00 8.00 6 Model Study name Exaustratics for each study Difference limit limit Zvaluep-Value -	5	Enguda et al., 2016 - 2-340 0.790 0.424 - 3.880 0.792 - 2.893 0.003 Gorgula et al., 2016 - 1.200 0.630 0.397 - 2.434 0.034 - 1.306 0.057 Nacci et al., 2008 - 2.430 0.330 0.320 0.102 - 1.257 0.003 - 1.591 0.4150 Almadori et al., 2006 - 0.330 0.320 0.102 - 1.257 0.003 - 1.591 0.4150 Almadori et al., 2006 - 4.320 0.320 0.102 - 1.257 0.003 - 1.591 0.4150 Almadori et al., 2002 - 3.200 0.472 0.223 - 4.252 - 3.275 0.490 0.000 Rawal et al. 2002 - 0.620 1.270 1.612 - 3.109 1.809 - 0.488 0.625 Random - 2.248 0.683 0.467 - 3.587 - 0.590 - 3.200 0.001 -0.00 0.00 4.00 Model Study name Statistics for each study Difference Limit Limit Z/Jaluep-Value Chang et al., 2016 - 1.30 0.37 - 2.50 - 0.10 2.12 0.03 Nacci et al., 2000 - 4.20 0.37 - 5.58 - 2.54 - 5.8 0.00	800 a
Model Study rame Statistics for each study Ofference Offerenc Offerenc	5	Enguda et al., 2016 - 2-340 0,790 0,624 - 3.889 0,792 - 2.963 0,003 Gorgula et al., 2010 - 1.200 0,630 0,397 - 2.434 0,034 - 1,306 0,057 Nacci et al., 2006 - 0.630 0,320 0,102 - 1.257 - 0.003 - 1.571 0,049 Annadori et al., 2006 - 0.630 0,320 0,102 - 1.257 - 0.003 - 1.571 0,049 Annadori et al., 2006 - 0.630 0,320 0,102 - 1.257 - 0.003 - 1.571 0,049 Annadori et al., 2006 - 0.630 0,320 0,102 - 1.257 - 0.003 - 1.571 0,049 Reval et al. 2002 - 0.620 1,270 1,812 - 3.109 1,809 - 0.488 0,625 Random - 2.248 0,883 0,467 - 3.587 - 0.909 - 3.220 0,001 Model Study.name Estimation Strained Emitt Imit Z-Valuep-Value Chang et al., 2016 - 1.05 0,11 - 1.71 - 0.39 - 3.14 0,00 Gorgula et al., 2001 - 1.30 0,37 - 2.50 - 0.10 - 2.12 0,33 Naoci et al., 2008 - 4.25 0,67 - 5.88 - 2.48 - 5.18 0,00 Eletheriadou et al., 2008 - 4.25 0,07 - 5.88 - 2.44 - 5.18 0,00	8.00 a
Model Study name -2,71 0.43 -4,00 -1,42 -0,20 -4,00 0,00 4,00 8,00 6 Model Study name Statistics for each study Difference in means and 95%CI Difference in means and 95%CI Difference in means Variance limit Init 5,42 -120 -080 -100 0,00 4,00 8,00 6 Difference in means and 95%CI Difference in means and 95%CI Difference in means and 95%CI	5	Engular et al., 2016 - 1-200 0.630 0.397 - 0.24-34 0.004 - 1.306 0.003 Gorgular et al., 2016 - 1-200 0.630 0.397 - 24-34 0.004 - 1.306 0.007 Nacci et al., 2008 - 4.200 0.480 0.426 - 1.527 - 0.003 - 1.977 0.049 Almadori et al., 2003 - 4.200 0.232 0.107 - 4.672 - 3.569 - 1.2911 0.000 Almadori et al., 2002 - 0.620 1.277 0.191 - 3.509 - 1.2911 0.000 Rawat et al. 2002 - 0.620 1.270 1.912 - 3.109 1.809 - 0.480 0.625 Randorm - 2.240 0.683 0.467 - 3.587 - 0.909 - 3.290 0.001 Model Studyname Statistics for each study Difference Innews Name Control 1.270 - 1.027 - 0.003 - 1.000 Almadori et al., 2006 - 4.25 0.67 - 5.88 - 2.64 - 5.18 0.00 Elefthenisticou et al., 2006 - 4.42 0.057 - 3.587 - 0.900 - 3.290 - 0.001	a
6 Model Study name Statistics for each study Difference In means variance limit Lower Upper In means variance limit Init Z-Valuep-Value Erugula et al., 2016 - 0.10 0.34 + 1.24 + 1.04 + 0.17 0.86 Nacci et al., 2006 - 0.55 0.35 + 1.71 0.61 + 0.53 0.35 Einterminicou et al., 2006 - 0.60 0.11 + 1.26 0.66 + 1.77 0.08 Remote tal., 2002 0.60 0.11 + 1.26 0.66 + 1.77 0.08 Remote tal., 2002 0.60 0.11 + 1.26 0.66 + 1.77 0.08 Remote tal., 2002 0.60 0.11 + 1.26 0.66 + 1.77 0.08 Remote tal., 2002 0.60 0.11 + 1.26 0.66 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.66 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.66 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.66 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.66 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.66 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.66 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.66 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.66 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.66 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.56 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.56 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.56 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.56 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.56 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.56 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.56 0.11 + 1.26 0.56 + 1.07 0.08 Remote tal., 2005 - 0.56 0.11 + 1.26 0.56 + 1.07 0.56 + 1.05 0.56 + 1.05 0.56 + 1.05 0.56 + 1.05 0.56 + 1.05 0.56 + 1.0	5	Enguda et al., 2016 - 2430 0,700 0,624 - 3,880 0,702 - 2493 0,003 Gorgula et al., 2016 - 1200 0,830 0,397 - 2434 0,034 - 1305 0,057 Nacci et al., 2008 - 2400 0,030 - 1307 0,049 Amadori et al., 2006 - 4630 0,220 0,102 - 1277 - 0.003 - 1371 0,049 Amadori et al., 2002 - 0.620 1,270 1,012 - 3,080 - 12911 0,000 Rewat et al. 2002 - 0.620 1,270 1,012 - 3,080 - 0.2101 0,000 Rewat et al. 2002 - 0.620 1,270 1,012 - 3,000 1,000 Rewat et al. 2002 - 0.620 1,270 1,012 - 3,000 1,000 Rewat et al. 2002 - 0.620 1,270 1,012 - 3,000 1,000 Rewat et al. 2002 - 0.620 1,270 1,012 - 3,000 1,000 - 0.0000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.0000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.000 - 0.0000 - 0.000 - 0.000 - 0.000 -	800 a
6 Model Study name Difference Erugula et al., 2016 Statistics for each study Difference Lower Upper in means Variance Erugula et al., 2016 Statistics for each study Difference Lower Upper in means Variance Erugula et al., 2016 Statistics for each study Difference Lower Upper in means variance Statistics for each study Difference Lower Upper in means and 95%CI Difference Statistics for each study Difference Statistics for each study Difference Statistics for each study Difference Statistics for each study Statistics for each study Difference Statistics for each study Difference Statistics for each study Statistics for each study Difference Statistics for each study Statistics for each study Statistic	5	Engular et al., 2016 -2.340 0.790 0.624 -3.880 0.792 -2.893 0.003 Gorgular et al., 2016 -1.200 0.630 0.397 -2.434 0.034 -1.306 0.057 Nacci et al., 2006 -2.800 0.480 -2.802 0.057 -0.000 -0.000 Eththerisadou et al., 2006 -0.630 0.320 0.102 -1.227 -0.001 -1.971 0.490 Almadori et al., 2006 -0.320 0.127 0.223 -2.528 -2.356 0.000 Randori et al., 2002 -0.620 1.270 1.612 -3.100 1.809 -0.480 0.625 Randori -2.248 0.803 0.467 -3.587 -0.900 -0.00 4.00 0.00 4.00 Model Btudy name Estistics for each study Difference in means and 95%C Difference in means and 95%C Difference in means and 95%C Model Btudy name Chang et al., 2016 -1.03 0.37 -2.50 -0.10 -2.12 0.30 Nacci et al., 2016 -1.30 0.37 -2.50 -0.10 -2.12 <th>0.00 a</th>	0.00 a
Model Statistics for each study Difference in means and 95% CI Difference in means Variance limit Lower Upper in means Variance limit Difference in means and 95% CI Erugula et al., 2010 -0.10 0.34 -1.24 1.04 -0.17 0.86 Gorgadu et al., 2000 -0.05 0.35 -1.71 0.86	5	Engular et al. 2016 - 1200 0.630 0.397 - 2434 0.074 - 1205 0.003 Gorgular et al. 2010 - 1200 0.630 0.397 - 2434 0.034 - 1305 0.057 Nacci et al. 2000 - 2000 0.480 - 2409 - 1.531 - 4.153 0.057 Almadori et al. 2000 - 4.230 0.230 0.102 - 1297 - 0.003 - 1397 0.049 Almadori et al. 2002 - 4.230 0.027 - 1297 - 0.030 - 1397 0.049 Almadori et al. 2002 - 0.620 1.270 1.012 - 3109 1.809 - 0.480 0.625 Random - 2.240 0.683 0.477 0.223 - 4.226 - 2.375 - 0.906 0.001 Model Study.name Random - 2.240 0.683 0.477 - 3.587 - 0.909 - 3.290 0.001 Model Study.name Model Study.name Chang et al. 2016 - 1.05 0.11 - 1.71 0.39 - 3.14 0.00 Almadori et al. 2002 - 4.83 0.07 - 305 - 2.91 - 12.80 0.00 Handori et al. 2002 - 4.83 0.07 - 305 - 2.91 - 12.80 0.00 Handori et al. 2002 - 4.83 0.07 - 305 - 2.91 - 12.80 0.00 Handori et al. 2002 - 4.83 0.07 - 305 - 2.91 - 12.80 0.00 Handori et al. 2002 - 4.83 0.07 - 305 - 2.91 - 12.80 0.00 Almadori et al. 2002 - 4.83 0.07 - 305 - 2.91 - 12.80 0.00 Almadori et al. 2002 - 4.80 0.15 - 4.68 - 3.1 4.10 0.00 Almadori et al. 2002 - 4.83 0.08 - 4.37 - 4.29 - 17.50 0.00 Almadori et al. 2002 - 2.08 0.17 - 4.12 - 4.12 0.00 0.00 Revel et al. 2002 - 2.08 0.17 - 4.12 - 4.12 0.00 0.00 Almadori et al. 2002 - 2.08 0.17 - 4.12 - 4.12 0.00 0.00 Almadori et al. 2002 - 2.08 0.17 - 4.12 - 4.12 0.00 0.00 Almadori et al. 2002 - 2.08 0.17 - 4.12 - 4.12 0.00 0.00 Almadori et al. 2002 - 2.08 0.17 - 4.12 - 4.12 0.00 0.00 Almadori et al. 2002 - 2.08 0.17 - 4.12 - 4.12 0.00 0.00 Almadori et al. 2002 - 2.08 0.17 - 4.12 - 4.12 0.00 0.00 Almadori et al. 2002 - 2.08 0.17 - 4.12 - 4.12 0.00 0.00 Almadori et al. 2002 - 4.00 0.00 4.00	8.00 11
Model Statistics for each study Difference in means and 95%Cl Difference Lower Upper Inmeans variance Lower Upper Init Net Zvalues-Value Erugula et al., 2016 -3.31 1.16 -5.42 -1.20 -3.08 0.00 Gorgulu et al., 2016 -0.10 0.34 -1.24 1.04 -0.10 0.84 Nacci et al., 2006 -0.26 0.35 -3.58 -2.02 -7.03 0.00 Eithbriadou et al., 2006 -2.80 0.16 -3.58 -2.02 -7.03 0.00 Armadori et al., 2002 0.60 0.11 -1.26 0.06 -1.77 0.08 Armadori et al., 2002 0.62 1.06 -1.07 0.68	5	Engula et al. 2016 - 1-200 0.630 0.397 - 24-34 0.004 - 1306 0.005 Gorgula et al. 2010 - 1-200 0.630 0.397 - 24-34 0.004 - 1306 0.007 Necci et al. 2000 - 2000 0.630 0.220 0.102 - 1.227 - 0.003 - 1.571 0.049 Almadori et al. 2000 - 4.630 0.220 0.102 - 1.227 - 0.003 - 1.571 0.049 Almadori et al. 2002 - 0.620 1.270 1.012 - 3.109 1.809 - 0.480 0.625 Random - 2.248 0.663 0.467 - 3.587 - 0.909 - 3.220 0.011 Model Study.name Statistics for each study Model Study.name Change tal. 2016 - 1.05 0.11 - 1.71 0.29 - 3.14 0.00 Eleftminiadou et al. 2006 - 4.25 0.677 - 5.68 - 2.64 - 5.18 0.00 Eleftminiadou et al. 2006 - 4.25 0.677 - 5.68 - 2.64 - 5.18 0.00 Eleftminiadou et al. 2006 - 4.25 0.677 - 5.68 - 2.64 - 5.18 0.00 Eleftminiadou et al. 2006 - 4.25 0.677 - 5.68 - 2.64 - 5.18 0.00 Eleftminiadou et al. 2005 - 4.23 0.07 - 3.68 - 2.64 - 5.18 0.00 Eleftminiadou et al. 2005 - 4.23 0.07 - 3.68 - 2.64 - 5.18 0.00 Almadori et al. 2005 - 4.23 0.07 - 3.58 - 3.24 - 1.28 0.00 Almadori et al. 2005 - 2.19 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.09 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.09 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.09 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.09 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.09 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.09 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.09 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.09 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.09 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.00 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.00 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.00 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.00 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.00 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.00 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 2.00 0.15 - 4.68 - 3.14 - 1.00 0.00 Almadori et al. 2005 - 4.68 - 3.14 - 1.00 0.00	8.00
Differance Lower Upper In mans/Variance Imit Imit Imit Imit Zvaluep-Value Erugula et al., 2016 -3.31 1.16 -5.42 -1.20 -3.68 0.00 Gorgulu et al., 2010 -0.10 0.34 +1.24 1.04 -0.17 0.86 Nacci et al., 2006 -0.55 0.35 +1.24 1.04 -0.17 0.86 Eleffitheridou et al., 2006 -0.55 0.35 +2.02 -7.03 0.00 Annadori et al., 2005 0.60 0.11 +1.26 0.60 -1.26 Annadori et al., 2002 0.62 1.60 -1.77 0.00	5	Enguda et al., 2016 1-2340 0.700 0.424 -3.880 0.702 - 2403 0.003 Gorgula et al., 2016 1-200 0.630 0.397 - 2434 0.034 -1365 0.057 Nacci et al., 2008 0.430 0.320 0.102 -1.227 0.003 -1.371 0.449 Amadori et al., 2003 0.420 1.227 1.027 - 3.06 -1.291 1 0.000 Amadori et al., 2002 0.420 1.270 1.127 - 3.109 1.889 0.488 0.625 Random - 2.248 0.683 0.467 - 3.587 0.909 -3.220 0.001 Model Study name Chang et al., 2016 -1.30 0.37 - 2.50 -0.10 -2.12 0.00 Amadori et al., 2006 0.418 0.027 - 3.587 0.909 -3.280 0.001 Model Study name Chang et al., 2016 -1.30 0.37 - 2.50 -0.10 -2.12 0.00 Amadori et al., 2006 -4.23 0.03 - 0.11 -1.71 -0.39 -3.14 0.00 Gorgula et al., 2010 -1.30 0.37 - 2.50 -0.10 0.21 0.00 Amadori et al., 2005 -4.23 0.03 -0.11 -0.27 -0.39 -3.14 0.00 Gorgula et al., 2010 -1.30 0.37 -2.50 -0.10 0.21 2 0.03 Amadori et al., 2005 -4.23 0.03 -0.15 -4.66 -3.14 -10.00 Amadori et al., 2005 -4.23 0.007 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.23 0.007 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.23 0.007 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.23 0.07 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.23 0.07 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.23 0.07 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.23 0.07 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.23 0.07 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.23 0.07 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.23 0.07 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.23 0.07 -3.58 -2.91 +1.28 0.00 Amadori et al., 2005 -4.28 0.00 -4.00 0.00 4.00 -4.00 -4.00 -4.00 0.00 4.00 -4.00 -4.00 -4.00 0.00 4.00 -4.00 -4.00 -4.00 0.00 4.00 -4.00 -4.00 0.00 4.00 -4.00 -4.00 0.00 4.00 -4.00 -4.00 0.00 4.00 -4.00	0.00
in means Variance limit Limit Z-Valuep-Value Erugula et al., 2016 -3.31 116 -5.42 -2.02 -0.00 0.00 Gorgula et al., 2010 -0.10 0.34 -1.24 1.04 -0.17 0.86 Nacci et al., 2006 -0.55 0.35 -1.71 0.61 -0.89 0.35 Eleftherisioux et al., 2006 -0.56 0.51 -1.74 0.61 -3.93 0.35 Amadori et al., 2005 -0.56 0.51 -1.74 0.61 -3.95 -4.94 Amadori et al., 2005 0.60 0.11 -1.26 0.06 -1.77 0.08 -4.94	5	Engular et al., 2016 -2.340 0.770 0.624 -2.868 0.003 Gorgular et al., 2010 -1.200 0.630 0.397 -2.434 0.004 -1.950 0.057 Nacci et al., 2000 -2.000 0.630 0.392 -2.434 0.001 -1.950 0.057 Amadori et al., 2000 -0.630 0.320 0.102 -1.277 0.003 1.971 0.494 Amadori et al., 2002 -0.300 0.472 0.223 -2.52 -2.57 -6.990 0.000 4.00 0.00 4.00 Rendom -2.240 0.680 0.477 .3287 -0.990 -3.280 0.001 -4.00 0.00 4.00 Model Study name Statistics for each study Dever Upper Inneans Variance limit Tat Zvaluep-value -0.00 4.00 0.00 4.00 Model Study name Statistics for each study Dever Upper Inneans 1.000 -0.17 -0.17 -0.17 -0.17 -0.17 -0.17 -0.17 -0.17 -0.17 -0.17 -0.17 -0.17 -0.17 -0.00 0.00 4.00 -0.00 -0.00	8.00 8.00
Eruguau et al., 2016 -3.31 1.16 -5.42 1.20 -3.08 0.00 Gorgulu et al., 2010 -0.10 0.34 -1.24 1.04 -0.17 0.86 Nacci et al., 2006 -0.55 0.53 -1.10 1.081 -0.93 0.35 Eleftheridadou et al., 2006 -2.80 0.16 -3.58 -2.02 -7.03 0.00 Atmadori et al., 2002 -0.60 0.11 -1.26 0.06 -1.77 0.08	5	Engula et al., 2016 -2.340 0.770 0.624 -2.880 0.003 Gorgula et al., 2016 -1.200 0.630 0.397 -2.434 0.034 -1.305 0.057 Nacci et al., 2006 -2.800 0.030 -1.205 0.057 -1.205 0.057 Amadori et al., 2006 -4.230 0.230 0.107 -1.677 0.049 -1.806 0.057 Amadori et al., 2002 -0.620 1.227 1.027 -1.827 -0.331 -1.971 0.469 Rendom -2.240 0.633 0.427 -2.234 -2.234 -2.200 0.001 -1.007 0.409 Amadori et al., 2002 -0.623 1.627 -1.627 -0.608 0.625 -0.00 -0.00 4.00 Model Study.name Statistics for each study Difference Dorer Upper -0.00 0.00 4.00 Model Study.name Statistics for each study Difference in means and 95% C -0.00 -0.00 4.00 Amadori et al., 2002 -0.84	8.00 3 8.00
Nacci et al., 2006 -0.56 0.35 -1.46 1.06 0.35 Eleftheriadou et al., 2006 -0.56 0.35 -2.62 -7.03 0.00 Annacot et al., 2005 -0.66 0.11 -1.26 0.61 -0.93 0.35 Heritadou et al., 2005 -2.60 0.16 -3.58 -2.02 -7.03 0.00 Annacot et al., 2002 -0.66 0.11 -1.26 0.06 -1.77 0.06 Raval et al., 2002 -0.62 1.60 -1.61 1.00 4.62	5	Enguda et al., 2016 -2:340 0.770 0:24:-3:880 0.003 0.003 Gorgula et al., 2016 -1:200 0:830 0.397 -2:434 0.003 1.005 0.007 Nacci et al., 2006 -2:000 0:803 0.320 0:102 -1:227 0:003 1.971 0.494 Amasdori et al., 2005 -4:230 0:320 0:107 4.872 -3:580 -1:2211 0:000 Amasdori et al., 2002 -0:202 1:277 1:272 1:012 -3:100 1:809 -0:488 0:625 Randori -2:248 0:803 0:467 -3:587 -0:909 -3:220 0:00 4:00 Model Study name Statistics for each study Difference in means and 95% C Difference in means and 95% C Mandori et al., 2010 -1:30 0:37 -2:50 -0:10 -2:1 0:00 4:00 Amasdori et al., 2005 -4:83 0:07 -3:68 -2:1 0:00 -4:00 0:00 4:00 Amasdori et al., 2005 -4:83 0:07 -3:28 -2:01 0:00 -4:00 0	8.00
Eleftheriadou et al., 2006 -2.80 0.16 -3.58 -2.02 -7.03 0.00 Amadori et al., 2005 -0.60 0.11 -1.26 0.06 -1.77 0.08 Raval et al., 2002 0.062 160 -1.66 3.10 0.49 0.62	5	Engula et al., 2016 -2.340 0.790 0.624 -2.898 0.003 Gorgula et al., 2016 -1.200 0.630 0.397 -2.434 0.034 -1.065 0.057 Nacci et al., 2006 -2.000 0.630 0.320 0.102 -1.207 0.000 0.667 Almadori et al., 2006 -4.320 0.520 0.107 -4.872 -3.580 -1.201 0.000 Almadori et al., 2006 -4.320 0.320 0.107 -4.872 -3.580 -1.201 0.000 Randori et al., 2002 -3.200 0.477 0.223 -2.23 -2.508 0.001 -4.00 0.00 4.00 Model Study name Estistics for each study Difference in means and 95% CO -4.00 0.00 4.00 Model Study name Estistics for each study Difference in means and 95% CO -4.00 0.00 4.00 Model Study name Estistics for each study Difference in means and 95% CO -4.00 0.00 4.00 Model Study name Estistics for each study 0.00 -4.00 0.00 4.	8.00 8.00
Almadori et al., 2005 -0.60 0.11 -1.26 0.06 -1.77 0.08	6	Engula et al., 2016 - 1-200 0.630 0.397 - 24-34 0.004 - 1306 0.007 Gorgula et al., 2016 - 1-200 0.630 0.397 - 24-34 0.004 - 1306 0.007 Nacci et al., 2008 - 2.000 0.008 0.488 - 4.269 - 1.531 - 4.153 0.000 Annadori et al., 2003 - 4.230 0.232 0.102 - 1.277 - 4.003 - 1.971 0.494 Annadori et al., 2003 - 4.230 0.323 0.107 - 4.672 - 3.587 - 2.909 0.001 Readem - 2.248 0.683 0.477 0.223 - 4.226 - 3.275 - 6.960 0.001 Readem - 2.248 0.683 0.477 - 0.257 - 0.909 - 3.290 0.001 Model Study.name Statistics for each study Difference In means and 92% C Model Study.name - 2.71 0.43 - 3.06 - 1.54 - 1.00 0.00 Annadori et al., 2002 - 2.00 - 3.43 0.017 - 3.587 - 4.90 0.00 Elefthinatious et al., 2003 - 0.43 0.015 - 1.46 - 3.14 - 1.00 0.00 Hancol et al., 2005 - 4.25 0.67 - 5.88 - 2.24 - 5.18 0.00 Annadori et al., 2005 - 4.25 0.67 - 5.88 - 2.24 - 5.18 0.00 Annadori et al., 2005 - 4.25 0.67 - 5.88 - 2.24 - 5.18 0.00 Annadori et al., 2005 - 4.25 0.67 - 5.88 - 2.24 - 5.18 0.00 Annadori et al., 2006 - 2.10 - 3.12 0.00 Annadori et al., 2002 - 2.00 0.15 - 4.66 - 3.14 - 1.00 0.00 Reavel et al., 2002 - 2.00 - 1.72 0.00 Annadori et al., 2005 - 4.25 0.67 - 5.88 - 2.24 - 5.18 0.00 Annadori et al., 2005 - 4.25 0.67 - 5.88 - 2.24 - 5.18 0.00 Annadori et al., 2005 - 4.25 0.67 - 5.88 - 2.24 - 5.18 0.00 Annadori et al., 2005 - 4.25 0.67 - 5.80 - 2.12 0.00 Annadori et al., 2006 - 0.41 - 1.22 0.00 Annadori et al., 2006 - 0.51 - 1.12 0.00 Annadori et al., 2005 - 4.25 0.67 - 1.22 8.00 Annadori et al., 2006 - 0.50 - 1.15 0.00 Annadori et al., 2006 - 0.51 - 1.12 0.00 Annadori et al., 2006 - 0.50 - 1.15 0.11 - 1.17 - 1.20 - 3.08 0.00 Cifference In means and 95% CI Model Study.name Statistics for each study Difference In means and 95% CI Model Study.name Statistics for each study Model Study.name Statistics fore	8.00 3 8.00
Raval et al., 2002 0.62 1.60 -1.86 3.10 0.49 0.62	5	Engular et al., 2016 -2.340 0.770 0.624 -2.868 0.003 Gorgular et al., 2016 -1.200 0.630 0.397 -2.434 0.0034 -1.205 0.005 Nacci et al., 2006 -2.600 0.680 0.320 0.102 -1.227 -0.003 1.971 0.464 Amasdori et al., 2005 -4.230 0.320 0.102 -1.227 -0.003 -1.971 0.469 Amasdori et al., 2005 -4.230 0.320 0.107 -4.872 -3.580 -1.2211 0.000 Randori -2.200 0.202 1.277 1.912 -3.100 1.890 -0.480 0.625 Randori -2.248 0.683 0.467 -5.587 -0.800 -0.20 4.00 0.00 4.00 Model Study name Statistics for each study Difference in means and 95% C Difference in means and 95% C -4.800 -5.211 -7.20 0.00 4.00 -4.00 0.00 4.00 Model Study name Statistics for each study Difference in means and 95% C -4.800 -5.21 -4.02 0.00 4.00	8.00 a 8.00
	6	Engula et al., 2016 - 1-200 0.630 0.397 - 2434 0.004 - 1365 0.007 Nacci et al., 2008 - 2400 0.630 0.397 - 2434 0.034 - 1365 0.057 Nacci et al., 2008 - 0.630 0.320 0.102 - 1.27 - 0.003 - 1.571 0.049 Annadori et al., 2006 - 0.630 0.320 0.102 - 1.27 - 0.003 - 1.571 0.049 Annadori et al., 2002 - 0.620 1.270 1.012 - 3.109 1.089 - 0.488 0.655 Random - 2.248 0.683 0.467 - 3.587 - 0.909 - 3.250 0.001 Model Study name Chang et al., 2016 - 1.30 0.37 - 2.50 - 0.10 - 2.12 0.00 Annadori et al., 2006 - 0.630 0.327 0.007 - 4.672 - 3.587 - 0.909 - 3.250 0.001 Model Study name Chang et al., 2016 - 1.30 0.37 - 2.50 - 0.10 - 2.12 0.03 Annadori et al., 2005 - 4.68 0.01 - 1.71 - 1.05 - 3.14 0.00 Gorgulu et al., 2010 - 1.30 0.37 - 2.50 - 0.10 - 2.12 0.03 Annadori et al., 2005 - 4.68 0.01 - 1.37 - 1.20 5.32 1.10 0.00 Annadori et al., 2005 - 4.68 0.01 - 1.37 - 1.20 5.32 1.20 0.00 Annadori et al., 2005 - 4.68 0.01 - 1.37 - 1.20 5.32 1.20 0.00 Annadori et al., 2005 - 4.68 0.01 - 1.42 - 4.12 0.00 Annadori et al., 2005 - 4.68 0.01 - 3.74 - 1.00 0.00 Reval et al., 2005 - 4.68 0.01 - 1.42 - 4.12 0.00 Annadori et al., 2005 - 4.68 0.01 - 3.52 1.20 0.02 Reval et al., 2005 - 4.68 0.01 - 5.52 1.20 0.00 Annadori et al., 2005 - 4.68 0.01 - 5.52 1.20 0.00 Annadori et al., 2005 - 4.68 0.01 - 5.52 1.20 0.00 Annadori et al., 2005 - 4.68 0.01 - 5.52 1.20 0.00 Annadori et al., 2005 - 4.60 0.01 - 5.52 1.20 0.00 Annadori et al., 2005 - 4.60 0.01 - 5.52 1.20 0.00 Annadori et al., 2005 - 4.60 0.01 - 5.52 1.20 0.00 Annadori et al., 2005 - 4.60 0.01 - 5.52 0.22 1.20 0.00 Annadori et al., 2005 - 0.55 0.35 - 1.71 0.68 0.00 Bitterence in means and 95%C	8.00 3 8.00
Random -1.15 0.34 -2.29 -0.01 -1.98 0.05	6	Engula et al., 2016 - 2340 0,770 0,24 - 3,880 - 0,702 - 2,803 0,003 Gorgula et al., 2016 - 1200 0,630 0,307 - 2434 0,034 - 1305 0,057 Nacci et al., 2008 - 4,200 0,308 0,202 0,102 - 1297 - 0,003 - 1397 0,049 Almadori et al., 2003 - 4,220 0,220 0,102 - 1297 - 0,003 - 1397 0,049 Almadori et al., 2002 - 0,620 1,270 1,012 - 3,107 1,049 Almadori et al., 2002 - 0,620 1,270 1,012 - 3,107 1,049 Model Study.name Extintics for each study Difference in means and 95% C Model Study.name Chang et al., 2016 - 1,05 0,01 - 1,27 0, 003 - 3,210 0,00 Almadori et al., 2002 - 4,872 - 3,587 - 0,909 - 3,290 0,001 Model Study.name Extintics for each study Difference in means and 95% C Model Study.name Chang et al., 2016 - 1,05 0,11 - 1,71 0,38 - 3,11 4 0,00 Almadori et al., 2003 - 4,83 0,08 - 5,37 - 4,29 - 1,726 0,00 Almadori et al., 2003 - 4,83 0,007 - 5,85 - 2,81 - 1,28 0,00 Eletheriadou et al., 2002 - 2,06 0,15 - 4,66 -3,14 - 1,000 0,00 Reaval et al., 2002 - 2,06 0,15 - 4,66 -3,14 - 1,000 0,00 Almadori et al., 2002 - 2,06 0,15 - 4,66 -3,14 - 1,000 0,00 Almadori et al., 2002 - 2,06 0,15 - 4,66 -3,14 - 1,00 0,00 Reaval et al., 2016 - 1,17 0,43 - 4,10 - 0,12 2 100 - 4,0	8.00 a 8.00
-8.00 -4.00 0.00 4.00 8.00	6	Engula et al., 2016 - 1-200 0.630 0.397 - 0.24-38.09.076 0.003 Gorgula et al., 2016 - 1-200 0.630 0.397 - 24-34 0.004 - 1.306 0.097 Nacci et al., 2008 - 0.800 0.390 0.420 - 1.297 - 0.003 - 1.971 0.049 Armadori et al., 2005 - 4.230 0.232 0.107 - 4.672 - 3.589 - 1.2911 0.000 Armadori et al., 2002 - 0.620 1.270 1.912 - 3.109 1.809 - 0.480 0.625 Random - 2.248 0.683 0.467 - 3.587 - 0.909 - 3.220 0.011 Model Study name Randori et al., 2005 - 0.620 1.270 1.912 - 3.109 1.809 - 0.480 0.625 Random - 2.248 0.683 0.467 - 3.587 - 0.909 - 3.220 0.011 Model Study name Randori et al., 2006 - 0.60 0.37 - 2.509 - 0.221 0.03 Nacci et al., 2006 - 4.25 0.677 - 5.687 - 0.909 - 3.290 0.001 Model Study name Randori et al., 2006 - 4.28 0.037 - 2.50 - 0.10 - 2.12 0.03 Nacci et al., 2006 - 4.23 0.037 - 2.50 - 0.10 - 2.12 0.03 Nacci et al., 2006 - 4.23 0.037 - 2.50 - 0.10 - 2.12 0.03 Nacci et al., 2006 - 4.23 0.037 - 2.50 - 0.10 - 2.12 0.03 Nacci et al., 2006 - 4.23 0.08 - 5.37 + 2.51 1.4 0.00 Eleftmeniadou et al., 2006 - 4.30 0.037 - 2.52 0.01 Armadori et al., 2006 - 4.48 0.01 - 2.52 1.2 0.03 Nacci et al., 2006 - 4.43 0.01 - 3.21 2.4 0.22 Random - 2.71 0.43 - 4.00 - 1.42 - 4.12 0.00 Armadori et al., 2006 - 4.48 0.01 - 5.37 - 1.20 - 3.08 0.00 Eleftmeniadou et al., 2006 - 1.40 0.142 - 4.12 0.00 Armadori et al., 2006 - 2.60 0.11 - 1.22 - 3.08 0.00 Armadori et al., 2006 - 0.50 0.15 - 4.68 - 3.14 - 1.00 0.00 Raval et al., 2006 - 0.50 0.15 - 4.68 - 3.14 - 1.00 0.00 Armadori et al., 2006 - 4.00 0.142 - 4.12 0.00 Armadori et al., 2006 - 4.00 0.10 - 4.12 - 4.12 0.00 Armadori et al., 2006 - 2.60 0.11 - 1.22 - 3.08 0.03 Armadori et al., 2006 - 2.60 0.11 - 1.28 0.02 - 7.03 0.00 Armadori et al., 2006 - 0.50 0.55 - 1.71 0.61 - 0.53 0.35 Eleftmeniadou et al., 2006 - 0.60 0.11 - 1.28 0.02 - 7.03 0.00 Armadori et al., 2005 - 0.60 0.11 - 1.28 0.049 0.62 Random - 1.15 0.34 - 2.29 - 0.01 1.98 0.05	8.00

Figure 2. The forest plots and the differences between group means from the meta-analyses about folate.

Articles	Country	Study Design	Cancer Type	Sample Size (Patients)	Sample Size (Controls)	Homocysteine Level in Patients, μ M/L	Homocysteine Level in Controls, μ M/L	Matched Factors between Patients and Controls and/or Adjusted for Confounding Factors
Akinmoladun and Arinola (18), 2019 ^a	Nigeria	Case-control	HNSCC	Total: 30; smokers: 19; nonsmokers: 11	Total: 30; smokers: 2; nonsmokers: 28	7.84 (Median)	8.44 (Median)	Not included in the meta-analysis
Palaskar et al. (24), 2022 ^a	India	Case-control	OSCC	Total: 40; smokers: 17; nonsmokers: 23	40; nonsmokers: 40	18.55 (Median)	16.85 (Median)	Not included in the meta-analysis
Bahramian et al. (25), 2023	Iran	Case-control	OSCC	21; nonsmokers	21; nonsmokers	3.71	2.01	Matched: Age, gender, normal renal function, no alcohol intake, no diseases affecting homocysteine, no vitamin B12 intake
Erugula et al. (13), 2016	India	Case-control	OSCC	Total: 30; smokers: 30	Total: 30; nonsmokers: 15; smokers: 15	23.58	Smokers: 17.46; nonsmokers: 10.76	Matched: No diseases affecting the outcome, not receiving affecting drugs
Fanidi et al. (17), 2015	10 European countries	Cohort	HNSCC	Total: 516; smokers: 256; ex-smokers ^b : 145; nonsmokers: 105; unknown: 10	Total: 516 (matched control); smokers: 104; ex-smokers: 184; nonsmokers: 214; unknown: 14	10.8	10.2 (Matched control)	Matched: Country, age, gender, not other cancer, date of blood collection
Gorgulu et al. (14), 2010	Turkey	Case-control	ISCC	Total: 60; smokers: 56; nonsmokers: 4	Total: 60; smokers: 30; non-smokers: 30	Ш.5	Smokers: 9.7; non-smokers: 8.7	Matched: Geographic area, age, low to moderate alcohol intake, normal renal function, no hepatic failure, no treceiving affecting drugs, no folic acid and vitamin B12 intake, no nutritional deficiency
Nacci et al. (15), 2008	Italy	Case-control	LSCC	Total: 25; smokers: 13; ex-smokers: 12	Total: 80; smokers: 25; ex-smokers: 30; nonsmokers: 25	20.57; smokers: 21.97; ex-smokers: 19.08	7.40; smokers: 7.84; ex-smokers: 7.40; nonsmokers: 6.88	Adjustment: Age, gender, alcohol intake, cardiovascular disease
Eleftheriadou et al. (12), 2006	Greece	Case-control	HNSCC	Total: 149; smokers: 131; nonsmokers: 18	Total: 150; smokers: 77; nonsmokers: 73	9.9	Smokers: 8.43; nonsmokers: 5.92	Matched: Geographic area, age, gender, no systematic alcohol intake, normal renal function, no folate intake
Almadori et al. (10), 2005	Italy	Case-control	HNSCC	Total: 144; smokers: 129; nonsmokers: 15	Total: 210; smokers: 90; nonsmokers: 120	13.4	Smokers: 9.1; nonsmokers: 8.7	Matched: Geographic area, age, gender, no habitual alcohol intake, normal renal function, no folate intake, no nutritional deficiency
Almadori et al. (9), 2002	Italy	Case-control	HNSCC	Total: 42; smokers: 39; nonsmokers: 3	Total: 210; smokers: 90; nonsmokers: 120	10.4	Smokers: 8.3; nonsmokers: 7.8	Matched: Geographic area, age, gender, low to moderate alcohol intake

Abbreviations: HNSCC, head and neck squamous cell carcinoma; LSCC, laryngeal squamous cell carcinoma; OSCC, oral squamous cell carcinoma.

^a This article was not included in the meta-analysis due to the lack of data for means and standard dev

^b Ex-smokers were regarded as non-smokers.

HNSCC patients (either non-smokers or non-smokers + smokers) were compared with the non-smoker controls (5.60 μ M/L), in meta-analysis No. 10 (Figure 3), the serum Hcy level of patients (either smokers or smokers + non-smokers) was also significantly higher than that of the smoker controls (3.56 μ M/L). Additionally, based on meta-analysis No. 12 in Figure 3, smoking controls had significantly higher serum Hcy levels than non-smoking healthy individuals (mean difference = 1.17 μ M/L, P-value = 0.02). According to the Begg and Mazumdar test, all meta-analyses showed no indication of publication bias. Also, the Egger regression tests were not significant, except for meta-analysis No. 7 in Table 5 (P-value = 0.047). The forest plots from the meta-analyses regarding Hcy are

displayed in Figure 3.

4. Discussion

Conflicting reports exist in the literature regarding the relationship of HNSCC with serum folate and Hcy levels. Most studies showed a significant association of HNSCC with folate (9-15, 17, 18) and Hcy (9, 10, 12, 13, 15, 17, 25). However, in others, no significant relationship of HNSCC with folate (16) and Hcy (14, 18, 26) was reported. The authors will discuss the results of different meta-analyses for folate and Hcy to verify the existence of an association between HNSCC and serum folate and Hcy levels.

Meta-analysis	Forest plot
7 7	
	Model Study name Statistics for each study Difference in means and 95% CI
	Difference Standard Lower Upper in means error Variance limit limit Z-Value p-Value
	Bahramian et al., 2022 12.570 5.280 27.883 2.220 22.920 2.380 0.017
	Fanidi et al., 2015 0.600 0.228 0.052 0.153 1.047 2.634 0.008
	Gorgulu et al., 2010 2.300 1.266 1.604 -0.182 4.782 1.816 0.069
	Eleftheriadou et al., 2006 2.690 0.292 0.085 2.118 3.262 9.219 0.000
	Almadori et al. 2005 4.530 0.792 0.628 2.977 6.083 5.719 0.000
	Random 4.726 0.996 0.973 2.793 6.659 4.792 0.000
	-20.00 -10.00 0.00 10.00 20.00
8	
	Model Study name Statistics for each study Difference in means and 95% Cl
	Difference Standard Lower Upper in means error Variance limit Iimit Z-Value p-Value
	Erugula et al., 2016 9.470 2.432 5.915 4.703 14.237 3.894 0.000
	Gorgulu et al., 2010 2.300 1.266 1.604 -0.182 4.782 1.816 0.069
	Nacci et al., 2008 13.170 1.259 1.585 10.703 15.637 10.462 0.000
	Eleftheriadou et al., 2006 2.690 0.292 0.085 2.118 3.262 9.219 0.000
	Almadori et al., 2005 4.530 0.792 0.628 2.977 6.083 5.719 0.000
	Random 4.486 0.992 0.984 2.542 6.430 4.523 0.000
	-15.00 -7.50 0.00 7.50 15.00
9	Nadal Budu anna - Phalistias far anab
	Model Study name Statistics for each study Difference in means and 95% Cl Difference Standard Lower Upper
	in means error Variance limit limit Z-Value p-Value
	Fanidi et al., 2015 0.600 0.228 0.052 0.153 1.047 2.634 0.008
	Gorgulu et al., 2010 2.300 1.266 1.604 -0.182 4.782 1.816 0.069
	Eleftheriadou et al. 2006 2 690 0 282 0 085 2 118 3 262 9 219 0 000
	Almadori et al., 2005 4.530 0.792 0.628 2.977 6.083 5.719 0.000
	Almadori et al., 2002 2.390 0.545 0.297 1.322 3.458 4.387 0.000
	Random 4.016 1.010 1.020 2.037 5.995 3.978 0.000
	-15.00 -7.50 0.00 7.50 15.0
10	
	Model Study name Statistics for each study Difference in means and 95% Cl Difference - Standard Lower Upper
	in means error Variance imit imit Z-Value p-Value
	Gorquiu et al., 2010 1.800 1.755 3.079 -1.639 5.239 1.026 0.305
	Nacci et al., 2008 14.130 3.014 9.083 8.223 20.037 4.688 0.000
	Eleftheriadou et al., 2006 1.470 0.386 0.149 0.714 2.228 3.812 0.000
	Almadori et al. 2005 4.300 1.164 1.331 2.039 6.561 3.727 0.000
	Fixed 2.000 0.316 0.100 1.381 2.619 0.329 0.000
	Random 3.555 1.006 1.011 1.584 5.526 3.535 0.000
	20.00 10.00 10.00 20.00
	-20.00 -10.00 0.00 10.00 20.00
11	
	Model Study name Statistics for each study Difference in means and 95% CI
	Difference Lower Upper
	in means Variance limit limit Z-Valuep-Value
	Bahramian et al., 2022 12.57 27.88 2.22 22.92 2.38 0.02
	Nacci et al. 2008 11.90 0.94 10.00 13.80 12.25 0.00
	Eleftheriadou et al., 2006 3.98 0.12 3.29 4.67 11.34 0.00
	Almadori et al., 2005 4.70 0.97 2.77 6.63 4.76 0.00
	Almadori et al., 2002 2.60 0.38 1.39 3.81 4.21 0.00
	Prancom 5.60 1.90 2.90 8.30 4.07 0.00
	-15.00 -7.50 0.00 7.50 15.00
12	
	Model Study name Statistics for each study Difference in means and 95%CI
	Difference Lower Upper
	in means Variance limit limit Z-Valuep-Value
	Erugula et al., 2016 6.70 10.74 0.28 13.12 2.04 0.04
	Nacci et al., 2008 0.66 0.13 -0.05 1.37 1.81 0.07
	Eleftheriadou et al., 2006 2.51 0.15 1.75 3.27 6.44 0.00
	Almadori et al., 2005 0.40 0.34 -0.73 1.53 0.69 0.49 -
	Random 1.17 0.25 0.19 2.16 2.34 0.02
	-8.00 -4.00 0.00 4.00 8.00

Figure 3. The forest plots and differences between group means from the meta-analyses regarding homocysteine.

Table 3. Risk of Bias of the Included Studies in the Systematic Review												
Authors	Q1 a	Q2 ^b	Q3 C	Q4 d	Q5 ^e	Q6 ^f	Q7 ^g	Q8 ^h	Q9 ⁱ	Q10 j	Total ^k , %	Risk of Bias ¹
Akinmoladun and Arinola (18)	Ν	Ν	U	Y	Y	Y	Y	Y	NA	Y	67	Moderate
Chang et al. (11)	Y	Ν	Y	Y	Y	Y	Y	Y	NA	Y	89	Low
Erugula et al. (13)	Ν	Y	Y	Y	Y	Y	Y	Y	NA	Y	89	Low
Fanidi et al. (17)	Y	Y	Y	Y	Y	Y	Y	Y	NA	Y	100	Low
Gorgulu et al. (14)	Y	Y	Y	Y	Y	Y	Ν	Y	NA	Y	89	Low
Nacci et al. (15)	Y	Y	Y	Y	Y	Y	Y	Y	NA	Y	100	Low
Eleftheriadou et al. (12)	Y	Y	Y	Y	Y	Y	Y	Y	NA	Y	100	Low
Almadori et al. (10)	Y	Y	Y	Y	Y	Y	Y	Y	NA	Y	100	Low
Almadori et al. (9)	Y	Y	Ν	Y	Y	Y	Y	Y	NA	Y	89	Low
Raval et al. (16)	Ν	Y	Y	Y	Y	Y	Y	Y	NA	Y	89	Low
Palaskar et al. (24)	Y	Ν	Y	Y	Y	Y	Ν	Y	NA	Y	78	Low
Bahramian et al. (25)	Y	Y	Y	Y	Y	Y	Y	Y	NA	Y	100	Low

Abbreviations: Y, yes; N, no; U, unclear; NA, not applicable; Q, question. ^a QI: Were the groups comparable other than the presence of disease in cases or the absence of disease in control?

^b Q2: Were cases and controls matched appropriately? Q3: Were the same criteria used to identify cases and controls?

d Q4: Was the exposure measured in a standard, valid, and reliable way? e Q5: Was the exposure measured the same way for cases and controls?

f Q6: Were confounding factors identified?

^g Q7: Were strategies to deal with confounding factors stated?

h Q8: Were outcomes assessed in a standard, valid, and reliable way for cases?

ⁱ Q9: Was the exposure period of interest long enough to be meaningful?

^j Q10: Was appropriate statistical analysis used?

k Total = ΣY /applicable items (not applicable (NA) items were excluded from the sum).

¹ The risk of bias was classified as low when the study reached a "yes" score of \geq 70, moderate when the study reached a "yes" score of 50 to 69%, and high when the study reached a "yes" score of < 49%.

Table 4. Results of Different Meta-analyses about the Relationship of Serum Folate Levels with Head and Neck Squamous Cell Carcinoma

No.	Meta-analysis	Number of Studies	He	Heterogeneity Test		Pul	olication Bias
			Qª	P-Value	I ^{2b} (%)	Egger Test (P-Value)	Begg and Mazumdar Test (P-Value)
1 ^c	Patients vs. controls (with no regard to smoking conditions in both groups)	9	208.0	< 0.001	96.2	0.80	0.68
2 ^d	Patients vs. controls (smokers or smokers + non-smokers in both groups)	8	194.9	< 0.001	96.4	0.80	1.00
3 ^e	Patients vs. controls (smokers + non-smokers in both groups)	7	188.2	< 0.001	96.8	0.95	0.88
4 ^f	Patients vs. smoker controls	7	71.6	< 0.001	91.6	0.82	0.65
5 ^g	Patients vs. non-smoker controls	7	100.9	< 0.001	94.1	0.39	0.65
6	Smoker controls vs. non-smoker controls	6	30.0	< 0.001	83.3	0.88	0.57

^a Cochran's measure of the heterogeneity of the studies.

^b Measure of the inconsistency among the studies.

^c Patients were compared with the controls without considering the smoking condition in both groups.

^d Either smokers or smokers + non-smokers were compared with the controls (either smokers or smokers + non-smokers), excluding one study that had only non-smoker participants in both groups. ^e Smokers + non-smokers were compared with the controls (smokers + non-smokers), excluding two studies that had solely smoker or non-smoker participants in either

group. ¹ Either smokers or smokers + non-smokers were compared with the smoker controls.

^g Either non-smokers or non-smokers + smokers were compared with the non-smoker controls.

4.1. Folate

The results of different meta-analyses showed significant differences between HNSCC patients and healthy controls. In meta-analysis No. 1, when HNSCC patients were compared with the control group without considering the group's smoking conditions, the serum folate level in patients was 2.29 ng/mL lower than in healthy individuals. The results did not considerably change when one or two studies with different smoking conditions were excluded from the meta-analysis; the

No.	Meta-analysis	Number of Studies	He	terogeneity	/ Test	Publication Bias		
			Qª	P-Value	I ^{2b} (%)	Egger Test (P-Value)	Begg and Mazumdar Test (P-Value)	
7 [¢]	Patients vs. controls (without regard to smoking conditions in both groups)	8	145.7	< 0.001	95.2	0.047	0.62	
8 ^d	Patients vs. controls (smokers or smokers + non-smokers in both groups)	7	141.6	< 0.001	95.8	0.06	0.45	
9 ^e	Patients vs. controls (smokers + non-smokers in both groups)	6	131.8	< 0.001	96.2	0.10	0.57	
10 ^f	Patients vs. smoker controls	6	23.6	< 0.001	78.8	0.06	0.19	
11 ^g	Patients vs. non-smoker controls	6	72.9	< 0.001	93.1	0.45	0.35	
12	Smoker controls vs. Non-smoker controls	6	19.7	0.001	74.7	0.73	0.19	

Table 5. Results of Different Meta-analyses about the Relationship of Serum Levels of Homocysteine with Head and Neck Squamous Cell Carcinoma

^a Cochran's measure of the heterogeneity among the studies.

^b Measure of the inconsistency among the studies.

^c Patients were compared with the controls without considering the smoking condition in both groups.

^d Either smokers or smokers + non-smokers were compared with the controls (either smokers or smokers + non-smokers), excluding one study that had only non-smoker participants in both groups.

^e Smokers + non-smokers were compared with the controls (smokers + non-smokers), excluding two studies that had solely smoker or non-smoker participants in either group.

^f Either smokers or smokers + non-smokers were compared with the smoker controls.

^g Either non-smokers or non-smokers + smokers were compared with the non-smoker controls.

mean difference ranged from -2.24 to -2.71 ng/mL. These results indicate the significant association of serum folate level with HNSCC.

Meta-analysis No. 6 (Table 3 and Figure 2) revealed that smoking controls had significantly lower serum folate levels than non-smoking healthy individuals (mean difference of -1.15 ng/mL). Some substances in tobacco smoke interact with folate and lower serum levels in smokers (27). Although the serum folate level in the smoking controls was lower compared to the non-smoking control samples, the magnitude of this difference was lower than in cases when patients were compared with either smoking, non-smoking, or smoking + non-smoking controls (ranging from -2.24 to -2.71). Therefore, the higher reduction in the serum folate level of the HNSCC patients couldn't be attributed to the smoking conditions alone, and cancerous patients had lower folate than the controls, especially smoking controls, with a mean difference of -2.25.

The main risk factors for HNSCC are smoking (1, 28-36), alcohol (1, 30-32, 35, 37, 38), aging (1, 31), human papillomavirus infection (39, 40), and genetic factors (41), which may have contributed to the reduced folate levels and the onset of HNSCC. However, smoking is regarded as the primary risk factor for HNSCC. In a review study, Hashibe et al. (30) concluded that smoking accounts for 70% of HNSCC patients. In another review article, Whiteman and Wilson (38) reported that smoking

contributed to a very high median population attributable fraction (PAF) of > 50% as the epidemiological measure for larynx cancer, and alcohol contributed to a high median PAF of 25 - 50\% for oral cavity, pharynx, and larynx cancers.

As mentioned earlier, the serum folate level in HNSCC patients was significantly lower than in both smoking and non-smoking controls. Folate mediates one-carbon metabolism and plays a critical role in several pathways, such as DNA synthesis, amino acid homeostasis, and antioxidant generation, and its deficiency adversely alters these pathways (42, 43). DNA methylation modifies gene expression and transmits epigenetic information through DNA replication and cell division (42). Folate deficiency may result in abnormal methylation of DNA, consequently altering the expression of cancer suppressor genes (44). Additionally, low folate conditions may stimulate uracil production and decrease thymidine synthesis in the DNA sequence during cell division (42, 45), increasing the frequency of chromosomal breaks and, presumably, the risk of carcinogenesis (45).

4.2. Homocysteine

The trend of differences between HNSCC patients and healthy controls for Hcy was similar to serum folate. When HNSCC patients were compared with controls without considering the smoking conditions in both groups (meta-analysis No. 7), the serum Hcy level was 4.73 μ M/L higher in the cancerous patients compared to the controls. After excluding one or two studies with different smoking conditions, the results didn't change drastically, and the difference between patients and controls ranged from 3.56 to 4.49 μ M/L Hcy. The lowest mean difference for Hcy (3.56 μ M/L) belonged to meta-analysis No. 10, where the patients, smokers or smokers + non-smokers, were evaluated against the smoker controls. However, when non-smokers or non-smoker + smoker patients were compared with non-smoker controls, the mean difference between the two groups for Hcy rose to 5.60 (meta-analysis No. 11). These results also show the significant association of serum Hcy with HNSCC, without considering the smoking conditions of the control groups. Although smoking controls also had significantly higher Hcy levels than non-smoking individuals (mean difference = 1.17 μ M/L), this difference was much lower than in the analysis where HNSCC patients were evaluated against healthy controls, regardless of the smoking situation (ranging from 3.56 to 5.60 μ M/L). Thus, similar to the findings for serum folate level, the increase in Hcy level in cancerous patients couldn't be attributed solely to the smoking habit, and HNSCC patients had higher Hcy than the controls (especially the smoker controls).

Folate acts as a methyl donor in the methionine cycle, while Hcy serves as an intermediate metabolite within this cycle (15, 46). Hcy metabolism is crucial for regulating methionine availability and DNA methylation. It is synthesized from methionine through two cofactors: S-adenosylmethionine and S-adenosylhomocysteine. The level of Hcy is maintained through the remethylation pathway, which converts Hcy to methionine, and the transsulfuration pathway, which converts Hcy to cysteine (47). Consequently, alterations in Hcy metabolism lead to hyperhomocysteinemia, which is associated with increased free radicals, induced oxidative stress, and possibly increased risks of cancers and other diseases (13, 48). One reason for the elevation in Hcy levels in HNSCC patients might be the reduction of serum folate, which affects Hcy metabolism (49, 50). Thus, the positive relationship between Hcy and HNSCC may be linked to folate deficiency, resulting in the accumulation of Hcy in the blood serum (17).

4.3. Folate and Homocysteine as Possible Biomarkers

Despite advancements in the treatment of HNSCC through surgery, radiotherapy, and chemotherapy, the disease still carries a low overall 5-year survival rate of about 40 percent (3, 51). Clinical examinations and biopsies often fail to detect HNSCCs, such as oral squamous cell carcinoma, in the early stages (52). Therefore, early diagnosis of these malignancies can reduce morbidity and mortality. Identifying biomarkers would be beneficial in

the early detection of these cancers (13, 53). Although Almadori et al. (10) stated that in patients with HNSCC, Hcy levels may not solely depend on folate levels but possibly are influenced by the heterogeneity of the HNSCC phenotype, our meta-analysis of included articles yielded similar results for serum folate and Hcy, both of which showed a significant relationship with HNSCC. Therefore, these biomarkers may prove useful in the early detection of HNSCCs.

There were some limitations in this research. The heterogeneity among the studies concerning confounding factors related to HNSCC patients and controls may have influenced the results.

4.4. Conclusions

The results of different meta-analyses in this study showed that the serum folate and Hcy levels of HNSCC patients were significantly lower and higher, respectively, than those of the control groups, regardless of the smoking condition in both groups. Although serum folate was significantly lower and serum Hcy was significantly higher in the smoking control groups compared to the non-smoking control groups, the magnitude of these differences was smaller when patients were compared with the healthy groups. In conclusion, our meta-analyses suggest a potential association of serum folate and Hcy levels with HNSCC. Therefore, these biochemical compounds may serve as biomarkers for the early detection of HNSCC onset in patients.

Acknowledgments

The authors would like to express their gratitude to Mr. Hossein Hosseini Fard for his help with the statistical analysis.

Footnotes

Authors' Contribution: M.M.V: Acquisition of data, analysis and interpretation of data, and drafting of the manuscript; A.B: Study concept and design, critical revision of the manuscript for important intellectual content, and administrative, technical, and material support; K.K: Study concept and design, acquisition of data, analysis and interpretation of data, critical revision of the manuscript for important intellectual content, and study supervision; F.S: Acquisition of data and drafting of the manuscript. All authors read and approved the final manuscript.

Conflict of Interests: None of the authors are employees of any organization that may gain or lose financially

through this publication. None of the authors gain or lose financially through this publication.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: This manuscript was approved by the Ethics Committee of Tabriz University of Medical Sciences, Tabriz, Iran (IR.TBZMED.REC.1400.1238).

Funding/Support: This article results from a DDS degree thesis supported non-financially by the Tabriz University of Medical Sciences, and no funding was received.

References

- Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. *Nat Rev Dis Primers*. 2020;6(1):92. [PubMed ID: 33243986]. [PubMed Central ID: PMC7944998]. https://doi.org/10.1038/s41572-020-00224-3.
- Thomas SJ, Penfold CM, Waylen A, Ness AR. The changing aetiology of head and neck squamous cell cancer: A tale of three cancers? *Clin Otolaryngol.* 2018;43(4):999–1003. [PubMed ID: 29770611]. https:// doi.org/10.1111/coa.13144.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. [PubMed ID: 33433946]. https://doi.org/10. 3322/caac.21654.
- Kong L, Birkeland AC. Liquid Biopsies in Head and Neck Cancer: Current State and Future Challenges. *Cancers (Basel)*. 2021;13(8). [PubMed ID: 33919778]. [PubMed Central ID: PMC8070729]. https://doi. org/10.3390/cancers13081874.
- Parkhitko AA, Jouandin P, Mohr SE, Perrimon N. Methionine metabolism and methyltransferases in the regulation of aging and lifespan extension across species. *Aging Cell*. 2019;18(6). e13034. [PubMed ID: 31460700]. [PubMed Central ID: PMC6826121]. https://doi.org/10.1111/acel.13034.
- Hanson HE, Liebl AL. The Mutagenic Consequences of DNA Methylation within and across Generations. *Epigenomes*. 2022;6(4). [PubMed ID: 36278679]. [PubMed Central ID: PMC9624357]. https://doi.org/10.3390/epigenomes6040033.
- Kaye AD, Jeha GM, Pham AD, Fuller MC, Lerner ZI, Sibley GT, et al. Folic Acid Supplementation in Patients with Elevated Homocysteine Levels. *Adv Ther.* 2020;**37**(10):4149–64. [PubMed ID: 32845472]. [PubMed Central ID: PMC7497502]. https://doi.org/10.1007/s12325-020-01474-z.
- Barnabe A, Alessio AC, Bittar LF, de Moraes Mazetto B, Bicudo AM, de Paula EV, et al. Folate, vitamin B12 and Homocysteine status in the post-folic acid fortification era in different subgroups of the Brazilian population attended to at a public health care center. *Nutr J.* 2015;14:19. [PubMed ID: 25886278]. [PubMed Central ID: PMC4354994]. https://doi.org/10.1186/s12937-015-0006-3.
- Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, et al. Serum folate and homocysteine levels in head and neck squamous cell carcinoma. *Cancer*. 2002;94(4):1006–11. [PubMed ID: 11920469]. https://doi.org/10.1002/cncr.10343.
- Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, et al. Serum levels of folate, homocysteine, and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia. *Cancer*. 2005;103(2):284–92. [PubMed ID: 15593092]. https://doi.org/10. 1002/cncr.20772.
- Chang H, Ma M, Ma R, Zhang C, Zeng W, Xing LQ. Folate deficiency and aberrant expression of cell adhesion molecule 1 are potential indicators of prognosis in laryngeal squamous cell carcinoma. Oncol

Lett. 2016;12(6):4510-4. [PubMed ID: 28105160]. [PubMed Central ID: PMC5228386]. https://doi.org/10.3892/ol.2016.5264.

- 12. Eleftheriadou A, Chalastras T, Ferekidou E, Yiotakis I, Kyriou L, Tzagarakis M, et al. Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine. *Anticancer Res.* 2006;**26**(3B):2345-8. [PubMed ID: 16821614].
- Erugula SR, Kandukuri MK, Danappanavar PM, Ealla KK, Velidandla S, Manikya S. Clinical Utility of Serum Homocysteine and Folate as Tumor Markers in Oral Squamous Cell Carcinoma - A Cross-Sectional Study. J Clin Diagn Res. 2016;10(10):ZC24–8. [PubMed ID: 27891452]. [PubMed Central ID: PMC5121798]. https://doi.org/10.7860/JCDR/2016/ 19656.8637.
- Gorgulu O, Selcuk T, Ozdemir S, Sayar C, Beyazit Y, Akbas Y. Evaluation of the roles of serum vitamin B(12), folate and homocysteine levels in laryngeal squamous cell carcinoma. *J Int Med Res.* 2010;**38**(6):2047–52. [PubMed ID: 21227009]. https://doi.org/10.1177/147323001003800619.
- Nacci A, Dallan I, Bruschini L, Traino AC, Panicucci E, Bruschini P, et al. Plasma homocysteine, folate, and vitamin B12 levels in patients with laryngeal cancer. *Arch Otolaryngol Head Neck Surg.* 2008;**134**(12):1328–33. [PubMed ID: 19075131]. https://doi.org/10.1001/archotol.134.12.1328.
- Raval GN, Sainger RN, Rawal RM, Patel JB, Patel BP, Jha FP, et al. Vitamin B(12) and Folate Status in Head and Neck Cancer. Asian Pac J Cancer Prev. 2002;3(2):155–62. [PubMed ID: 12718595].
- Fanidi A, Relton C, Ueland PM, Midttun O, Vollset SE, Travis RC, et al. A prospective study of one-carbon metabolism biomarkers and cancer of the head and neck and esophagus. *Int J Cancer*. 2015;**136**(4):915–27. [PubMed ID: 24975698]. https://doi.org/10.1002/ijc.29051.
- Akinmoladun VI, Arinola OG. Serum levels of single-carbon metabolism vitamins and homocysteine in head-and-neck squamous cell carcinoma: Preliminary report. Ann Afr Med. 2019;18(2):60-4. [PubMed ID: 31070145]. [PubMed Central ID: PMC6521640]. https://doi.org/10.4103/aam.aam_18_18.
- Palaskar SJ, Mukkanwar RN, Joshi K. Folate Mediated One Carbon Metabolism in Head and Neck Squamous Cell Carcinoma: A Systematic Review. J Clin Diagn Res. 2022;16(7):9-12. https: //doi.org/10.7860/jcdr/2022/55378.16606.
- Porritt K, Gomersall J, Lockwood C. JBI's Systematic Reviews: Study selection and critical appraisal. *Am J Nurs*. 2014;**114**(6):47-52. [PubMed ID: 24869584]. https://doi.org/10.1097/01.NAJ.0000450430. 97383.64.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;**327**(7414):557-60. [PubMed ID:12958120]. [PubMed Central ID: PMC192859]. https://doi.org/10.1136/bmj.327.7414.557.
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;**315**(7109):629–34. [PubMed ID: 9310563]. [PubMed Central ID: PMC2127453]. https://doi. org/10.1136/bmj.315.7109.629.
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. 1994;**50**(4):1088-101. [PubMed ID: 7786990].
- Palaskar S, Joshi K, Mukkanwar R, Pawar R, Kulkarni G, Pawar S. Utility of serum homocysteine in oral squamous cell carcinoma patients as a potential biomarker. J Oral Maxillofac Pathol. 2022;26(3):335–9. [PubMed ID: 36588856]. [PubMed Central ID: PMC9802518]. https:// doi.org/10.4103/jomfp.jomfp.268_22.
- Bahramian A, Dabaghi Tabriz F, Katebi K, Jafarlou V, Motayagheni R, Joudi A. Comparison of salivary and serum homocysteine levels in oral squamous cell carcinoma. *J Oral Health Oral Epidemiol.* 2023;**12**(1):38–41. https://doi.org/10.34172/johoe.2023.07.
- 26. Jaganath S, Kaveri H, Okade A. Determination of plasma homocysteine levels in oral submucous fibrosis & oral squamous cell carcinoma using high performance liquid chromatography and its plausibility as a potential biomarker. World J Pharm Res. 2016;5(4):1125–41.

- Tuenter A, Bautista Nino PK, Vitezova A, Pantavos A, Bramer WM, Franco OH, et al. Folate, vitamin B12, and homocysteine in smoking-exposed pregnant women: A systematic review. *Matern Child Nutr.* 2019;15(1). e12675. [PubMed ID: 30182513]. [PubMed Central ID: PMC6585731]. https://doi.org/10.1111/mcn.12675.
- Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. *Lancet*. 2008;**371**(9625):1695-709. [PubMed ID: 18486742]. [PubMed Central ID: PMC7720415]. https://doi.org/10.1016/S0140-6736(08)60728-X.
- Chang ET, Liu Z, Hildesheim A, Liu Q, Cai Y, Zhang Z, et al. Active and Passive Smoking and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China. *Am J Epidemiol.* 2017;**185**(12):1272–80. [PubMed ID: 28459936]. [PubMed Central ID: PMC5860561]. https://doi.org/10.1093/aje/kwx018.
- Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Cancer Epidemiol Biomarkers Prev.* 2009;18(2):541–50. [PubMed ID: 19190158]. [PubMed Central ID: PMC3051410]. https://doi.org/10.1158/1055-9965.EPI-08-0347.
- Idel C, Loyal K, Rades D, Hakim SG, Schumacher U, Bruchhage KL, et al. Smoking-, Alcohol-, and Age-Related Alterations of Blood Monocyte Subsets and Circulating CD4/CD8 T Cells in Head and Neck Cancer. *Biology (Basel)*. 2022;11(5). [PubMed ID: 35625386]. [PubMed Central ID: PMC9138171]. https://doi.org/10.3390/biology11050658.
- Jethwa AR, Khariwala SS. Tobacco-related carcinogenesis in head and neck cancer. *Cancer Metastasis Rev.* 2017;36(3):411–23. [PubMed ID: 28801840]. [PubMed Central ID: PMC5709040]. https://doi.org/10.1007/s10555-017-9689-6.
- 33. Osazuwa-Peters N, Adjei Boakye E, Chen BY, Tobo BB, Varvares MA. Association Between Head and Neck Squamous Cell Carcinoma Survival, Smoking at Diagnosis, and Marital Status. JAMA Otolaryngol Head Neck Surg. 2018;144(1):43–50. [PubMed ID: 29121146]. [PubMed Central ID: PMC5833596]. https://doi.org/10.1001/jamaoto.2017.1880.
- Schrank T, Weir W, Lal A, Landess L, Lenze N, Hackman T. Quantifying smoking exposure, genomic correlates, and related risk of treatment failure in p16+ squamous cell carcinoma of the oropharynx. *Laryngoscope Investig Otolaryngol*. 2021;6(6):1376-82. [PubMed ID: 34938877]. [PubMed Central ID: PMC8665424]. https://doi.org/10.1002/lio2.695.
- Shaw R, Beasley N. Aetiology and risk factors for head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S9–S12. [PubMed ID: 27841107]. [PubMed Central ID: PMC4873944]. https://doi.org/10.1017/S0022215116000360.
- 36. Wyss A, Hashibe M, Chuang SC, Lee YC, Zhang ZF, Yu GP, et al. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *Am J Epidemiol*. 2013;**178**(5):679–90. [PubMed ID: 23817919]. [PubMed Central ID: PMC3755640]. https://doi. org/10.1093/aje/kwt029.
- Praud D, Rota M, Rehm J, Shield K, Zatonski W, Hashibe M, et al. Cancer incidence and mortality attributable to alcohol consumption. *Int J Cancer*. 2016;**138**(6):1380–7. [PubMed ID: 26455822]. https://doi.org/10. 1002/ijc.29890.
- Whiteman DC, Wilson LF. The fractions of cancer attributable to modifiable factors: A global review. *Cancer Epidemiol*. 2016;44:203–21. [PubMed ID: 27460784]. https://doi.org/10.1016/j.canep.2016.06.013.
- Chaturvedi AK. Epidemiology and clinical aspects of HPV in head and neck cancers. *Head Neck Pathol*. 2012;6 Suppl 1(Suppl 1):S16–24. [PubMed ID: 22782220]. [PubMed Central ID: PMC3394159]. https://doi. org/10.1007/s12105-012-0377-0.

- Stein AP, Saha S, Kraninger JL, Swick AD, Yu M, Lambert PF, et al. Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic Review. *Cancer J.* 2015;21(3):138-46. [PubMed ID: 26049691]. [PubMed Central ID: PMC4459520]. https://doi.org/10.1097/PPO.000000000000115.
- Gingerich MA, Smith JD, Michmerhuizen NL, Ludwig M, Devenport S, Matovina C, et al. Comprehensive review of genetic factors contributing to head and neck squamous cell carcinoma development in low-risk, nontraditional patients. *Head Neck*. 2018;40(5):943-54. [PubMed ID: 29427520]. [PubMed Central ID: PMC5912962]. https://doi.org/10.1002/hed.25057.
- Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. *Adv Nutr.* 2012;3(1):21–38. [PubMed ID: 22332098]. [PubMed Central ID: PMC3262611]. https://doi.org/10.3945/an.111.000992.
- Lyon P, Strippoli V, Fang B, Cimmino L. B Vitamins and One-Carbon Metabolism: Implications in Human Health and Disease. *Nutrients*. 2020;**12**(9). [PubMed ID: 32961717]. [PubMed Central ID: PMC7551072]. https://doi.org/10.3390/nu12092867.
- Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr. 2000;130(2):129–32. [PubMed ID: 10720158]. https://doi.org/10. 1093/jn/130.2.129.
- Duthie SJ, Grant G, Narayanan S. Increased uracil misincorporation in lymphocytes from folate-deficient rats. *Br J Cancer*. 2000;83(11):1532-7. [PubMed ID: 11076664]. [PubMed Central ID: PMC2363426]. https:// doi.org/10.1054/bjoc.2000.1481.
- 46. Mandaviya PR, Stolk L, Heil SG. Homocysteine and DNA methylation: a review of animal and human literature. *Mol Genet Metab.* 2014;**113**(4):243–52. [PubMed ID: 25456744]. https://doi.org/10.1016/j.ymgme.2014.10.006.
- Rehman T, Shabbir MA, Inam-Ur-Raheem M, Manzoor MF, Ahmad N, Liu ZW, et al. Cysteine and homocysteine as biomarker of various diseases. *Food Sci Nutr.* 2020;8(9):4696–707. [PubMed ID: 32994931]. [PubMed Central ID: PMC7500767]. https://doi.org/10.1002/fsn3.1818.
- Koklesova L, Mazurakova A, Samec M, Biringer K, Samuel SM, Busselberg D, et al. Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person. *EPMA J.* 2021;**12**(4):477-505. [PubMed ID: 34786033]. [PubMed Central ID: PMC8581606]. https://doi.org/10.1007/s13167-021-00263-0.
- Hasan T, Arora R, Bansal AK, Bhattacharya R, Sharma GS, Singh LR. Disturbed homocysteine metabolism is associated with cancer. *Exp Mol Med*. 2019;**51**(2):1-13. [PubMed ID: 30804341]. [PubMed Central ID: PMC6389897]. https://doi.org/10.1038/s12276-019-0216-4.
- Kilic N, Dagli N, Aydin S, Erman F, Bek Y, Akin O, et al. Saliva/serum ghrelin, obestatin and homocysteine levels in patients with ischaemic heart disease. *Cardiovasc J Afr.* 2017;28(3):159–64. [PubMed ID: 28759087]. [PubMed Central ID: PMC5558140]. https://doi.org/10.5830/CVJA-2016-075.
- Kabzinski J, Maczynska M, Majsterek I. MicroRNA as a Novel Biomarker in the Diagnosis of Head and Neck Cancer. *Biomolecules*. 2021;11(6). [PubMed ID: 34198889]. [PubMed Central ID: PMC8228566]. https://doi.org/10.3390/biom11060844.
- Rao RS, Chatura KR, Sv S, Prasad K, Lakshminarayana S, Ali FM, et al. Procedures and pitfalls in incisional biopsies of oral squamous cell carcinoma with respect to histopathological diagnosis. *Dis Mon*. 2020;66(12):101035. [PubMed ID: 32622677]. https://doi.org/10.1016/j. disamonth.2020.101035.
- Rivera C, Oliveira AK, Costa RAP, De Rossi T, Paes Leme AF. Prognostic biomarkers in oral squamous cell carcinoma: A systematic review. *Oral Oncol.* 2017;**72**:38–47. [PubMed ID: 28797460]. https://doi.org/10. 1016/j.oraloncology.2017.07.003.